

2013 Fact Book

National Cancer Institute

2013 Fact Book

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

The information set forth in this publication is compiled and amended annually by the budget and finance staff of the National Cancer Institute and is intended primarily for the use by members of the Institute and others involved in the administration and management of the National Cancer Program. It is available online at www.cancer.gov. Questions regarding any of the information contained herein may be directed to the Office of Budget and Finance, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland, 20892

Table of Contents

Budget Overview	Fiscal Year 2013 NCI Budget in Review	iii
Organization	NCI Director's Biography	O-1
	Former Directors of the NCI	O-2
	National Cancer Advisory Board	O-4
	NCI-Frederick Advisory Committee	O-8
	Clinical Trials and Translational Research Advisory Committee	O-10
	Boards of Scientific Counselors and Advisors	O-12
	President's Cancer Panel	O-13
	NCI Scientific Program Leaders	O-13
	NCI Director's Consumer Liaison Group	O-14
	Operational Organization Charts:	
	National Cancer Institute	O-15
	Office of the Director	O-16
	OD I: Office of Management	O-17
	OD II: Center for Biomedical Informatics and Information Technology	O-18
	OD II: Office of Science Planning and Assessment	O-18
	OD III: Office of Communications and Education	O-19
	OD IV: Center for Cancer Training	O-20
	OD IV: Center for Cancer Genomics	O-20
	OD V: Center for Strategic and Scientific Initiatives	O-21
	OD V: Center to Reduce Cancer Health Disparities	O-21
	Center for Cancer Research	O-22
	Center for Cancer Research (continued)	O-23
	Division of Cancer Biology	O-24
	Division of Cancer Epidemiology and Genetics	O-25
	Division of Cancer Prevention	O-26
	Division of Cancer Control and Population Sciences	O-27
	Division of Cancer Treatment and Diagnosis	O-28
	Division of Extramural Activities	O-29
Cancer Statistics	Links to Cancer Statistics	C-1
NCI Budget Data	NCI Budget	B-1
	Program Structure	B-2
	Extramural Funds	B-3
	NCI Obligations by Mechanism	B-4/5
	NIH Management Fund, Service & Supply Funds, GSA Rent	B-6
	Special Sources of Funds	B-7
	Funding for Various Research Areas	B-8
NCI Extramural Programs	Research Project Grants (RPGs) Summary	E-1
	RPGs Number of Awards	E-2
	RPGs Requested and Awarded	E-3
	RPGs Awards by Grant Activity Codes	E-4

	Activity Code Descriptions	E-5
	RPG Funding Mechanisms – Paylines and Percent Share	E-6
	Cancer Centers by State	E-7
	Specialized Programs of Research Excellence (SPOREs)	E-8
	National Research Service Awards (NRSAs)	E-9
	Research Career Awards “K” Program	E-10
	Grant and Contract Awards by State	E-11
	Grant and Contract Awards by Country	E-12
	Institutions Receiving More than \$15 Million in NCI Support	E-13
Historical Trends	Appropriations of the NCI	H-1
	Professional Judgment (Bypass) Budget Requests	H-2
	Bypass Requests and NCI Appropriations	H-3
	Funding Trends	H-4
	Extramural vs. In-house Funding	H-5
	Comparison of Dollars, Positions, and Space	H-6
	NCI Personnel	H-7
	AIDS Funding History	H-8

Changes to the 2013 NCI Fact Book

In the 2013 edition of the NCI Fact Book, the Budget Overview that appears as the first section of the book contains high-level, summary information about the NCI budget. In previous years, the first section of the Fact Book contained additional types of tables and charts. For the 2013 edition, we relocated these additional tables and charts to other sections of the Fact Book.

For example, the following tables and charts that display budget trends during the past five years now appear in the Historical Trends section:

- Percent Share of Total NCI Dollars
- Historical Funding Trends
- Percent Growth by Mechanism
- Extramural vs. In-house Funding.

The following tables and charts that display detailed extramural information now appear in the Extramural Programs section:

- Research Project Grants Table
- Grant Funding Paylines Table
- Percent Share of Total RPG Funds Chart
- Research Career “K” Awards Program Table and Chart.

The 2013 NCI Fact Book is also online at <http://obf.cancer.gov/> or www.cancer.gov.

Budget Overview

Fiscal Year 2013 NCI Budget in Review

This section provides a brief summary of the distribution of the NCI Fiscal Year 2013 budget. Additional information on the NCI budget is accessible from the NCI Home Page (<http://www.cancer.gov>).

Summary

FY 2013 funds available to the NCI totaled \$4.789 billion, reflecting a decrease of 5.5 percent, or \$278 million from the previous fiscal year.

Fiscal highlights:

- Of the total NCI budget, 41.8 percent of the funds were allocated for Research Project Grants (RPGs).
- The total number of RPGs funded was 4,816 (including SBIR).
- Almost one-fourth of the RPGs awarded were new (Type 1) or competing renewal (Type 2) awards.
- NCI funded 1,095 competing RPGs.
- Almost one-third of the total NCI budget supported ongoing, non-competing (Type 5) RPGs.
- R01 grants were funded to the 9th percentile.
- 159 grants – totaling over \$71 million – were funded as Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards.
- Intramural Research comprised 17 percent of the total NCI budget. Of this amount, about 79 percent was for Labs and Bench Research and the remaining was for infrastructure and support.


NCI Budget by Mechanism for FY 2012 and 2013
(Dollars in Thousands)

	FY 2012	FY 2013	Change FY 2012 to FY 2013	
			Amount	Percent
Research Project Grants:				
Noncompeting	\$1,639,445	\$1,486,513	-\$152,932	-9.3%
Admin Supplements	19,819	38,443	18,624	94.0%
Competing	414,004	403,945	-10,059	-2.4%
Subtotal, RPG	2,073,268	1,928,901	-144,367	-7.0%
SBIR/STTR	77,355	71,260	-6,095	-7.9%
Total, RPGs	2,150,624	2,000,161	-150,463	-7.0%
Cancer Centers	279,877	262,232	-17,645	-6.3%
SPOREs	113,454	104,296	-9,158	-8.1%
Other P50s/P20s	33,438	21,467	-11,971	-35.8%
Other Specialized Centers	186,020	145,956	-40,064	-21.5%
Total, Centers, Spec Ctrs, & SPOREs	612,789	533,951	-78,838	-12.9%
Research Career Program	73,164	67,525	-5,639	-7.7%
Cancer Education	33,372	34,466	1,094	3.3%
Clinical Cooperative Groups	229,842	235,443	5,601	2.4%
Other Grants	71,164	50,104	-21,060	-29.6%
Subtotal, Other	407,542	387,538	-20,004	-4.9%
Total, Research Grants	3,170,954	2,921,650	-249,304	-7.9%
National Research Service Awards	65,992	65,788	-204	-0.3%
R&D Contracts	589,715	616,046	26,331	4.5%
Intramural Research	857,841	811,572	-46,269	-5.4%
Research Management & Support	374,919	366,054	-8,865	-2.4%
Construction	0	0	0	0.0%
Buildings and Facilities	7,920	7,904	-16	-0.2%
Total, NCI	\$5,067,342 *	\$4,789,014 *	-\$278,328	-5.5%
AIDS research amounts included above	[271,692]	[261,550]	[1,739]	0.6%

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.

FY 2013 Actual Obligations by Mechanism (Dollars in Millions)

Total FY 2013 Actual Obligations = \$4.789 Billion



*Other Mechanisms category includes the following: Cancer Education, Cooperative Groups, NRSAs, RMS, Construction, and Buildings and Facilities.

National Cancer Institute

Director's Biography Harold Varmus, M.D.

Harold Varmus became Director of the National Cancer Institute on July 12, 2010.

Harold Varmus, co-recipient of the Nobel Prize for studies of the genetic basis of cancer, became Director of the National Cancer Institute on July 12, 2010, after 10 years as President of Memorial Sloan-Kettering Cancer Center and six years as Director of the National Institutes of Health. He is a member of the U.S. National Academy of Sciences and the Institute of Medicine and is involved in several initiatives to promote science and health in developing countries. The author of over 350 scientific papers and five books, including a recent memoir titled The Art and Politics of Science, he was a co-chair of President Obama's Council of Advisors on Science and Technology, was a co-founder and Chairman of the Board of the Public Library of Science, and chaired the Scientific Board of the Gates Foundation Grand Challenges in Global Health.

Former Directors of the National Cancer Institute

John E. Niederhuber, M.D.
September 2006 – July 2010
June 2006 – September 2006 (Acting)

Dr. Niederhuber became NCI Director in September 2006 after serving as Acting Director since June 2006. He joined NCI in September 2005, serving as Deputy Director for Translational and Clinical Sciences and Chief Operating Officer. Prior to joining NCI, Dr. Niederhuber served as the Chair of the National Cancer Advisory Board, as an external NCI advisor and grant reviewer, and as a laboratory investigator supported by NCI and the NIH.

Andrew C. von Eschenbach, M.D.
January 2002 – September 2005

Dr. von Eschenbach became the NCI Director in January 2002. He previously directed the Genitourinary Cancer Center and the Prostate Cancer Research Program at The University of Texas M.D. Anderson Cancer Center.

Richard D. Klausner, M.D.
August 1995 – September 2001

Dr. Klausner was appointed NCI Director in August 1995. From 1984 to 1997 he was Chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health & Human Development.

Samuel Broder, M.D.
December 1988 – March 1995

Dr. Broder joined NCI in 1972 as a Clinical Associate in the Metabolism Branch. In 1981, he became Associate Director for NCI's Clinical Oncology Program.

Vincent T. DeVita, Jr., M.D.
July 1980 – August 1988
January 1980 – June 1980 (Acting)

Dr. DeVita joined NCI in 1963 as a Clinical Associate in the Laboratory of Chemical Pharmacology. Prior to his appointment as Director, he was head of the Solid Tumor Service, Chief of the Medicine Branch, Director of the Division of Cancer Treatment, and Clinical Director.

Arthur Canfield Upton, M.D.
July 1977 – December 1979

Prior to his tenure as NCI Director, Dr. Upton served as Dean of the School of Basic Health Sciences at the State University of New York at Stony Brook.

Frank Joseph Rauscher, Jr., Ph.D.
May 1972 – October 1976

Dr. Rauscher served as Scientific Director for Etiology, NCI, prior to his appointment as Director of NCI in 1972.

Carl Gwin Baker, M.D.
July 1970 – April 1972
November 1969 – July 1970 (Acting)

During his tenure with the Public Health Service (PHS), Dr. Baker served as Scientific Director for Etiology, NCI, and as Acting Director of NCI prior to his appointment as Director in July 1970.

Kenneth Milo Endicott, M.D.
July 1960 – November 1969

Dr. Endicott served as Chief of the Cancer Chemotherapy National Service Center, PHS, and as Associate Director, NIH, prior to being appointed Director of NCI in July 1960.

John Roderick Heller, M.D.
May 1948 – June 1960

Dr. Heller joined PHS in 1934 and became Chief of the Venereal Disease Division prior to his appointment as Director of NCI in 1948.

Former Directors of the National Cancer Institute (continued)

Leonard Andrew Scheele, M.D.
July 1947 – April 1948

Dr. Scheele served in various capacities during his tenure with PHS prior to his appointment as Assistant Chief and, subsequently, Director of NCI in July 1947.

Roscoe Roy Spencer, M.D.
August 1943 – July 1947

Dr. Spencer became NCI's first Assistant Chief and, subsequently, was appointed Director of the Institute in 1943.

Carl Voegtlin, Ph.D.
January 1938 – July 1943

Dr. Voegtlin served as Professor of Pharmacology and Chief of the Division of Pharmacy at the Hygienic Laboratory prior to becoming the first Director of NCI in 1938.

National Cancer Advisory Board (NCAB)

Membership and Term

Chair

- 2016 Tyler E. Jacks, Ph.D.
Director
Koch Institute for Integrative Cancer Research
David H. Koch Professor of Biology
Massachusetts Institute of Technology
Cambridge, MA 02157
- 2014 Victoria L. Champion, D.N.S.
Associate Dean for Research
Mary Margaret Walther Distinguished
Professor of Nursing
Center for Research & Scholarship
Indiana University School of Nursing
Indianapolis, IN 46202
- 2018 David C. Christiani, M.D., M.P.H.
Elkan Blout Professor of Environmental Genetics
Department of Environmental Health
Department of Epidemiology
Harvard School of Public Health
Professor of Medicine
Harvard Medical School
Boston, MA 02115
- 2016 Marcia R. Cruz-Correa, M.D., Ph.D.
Associate Professor of Medicine and Biochemistry
University of Puerto Rico
Basic and Translational Science Director
University of Puerto Rico
Comprehensive Cancer Center
San Juan, Puerto Rico
- 2016 Kevin J. Cullen, M.D.
Director
Marlene and Stewart Greenebaum Cancer Center
Professor of Medicine
University of Maryland
Baltimore, MD 21201
- 2018 Judy E. Garber, M.D., M.P.H.
Director
Center for Cancer Genetics and Prevention
Dana Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA 02215
- 2014 William H. Goodwin, Jr., M.B.A.
Chairman and President
CCA Industries, Inc.
Richmond, VA 23219
- 2014 Waun Ki Hong, M.D.
Professor
Head, Division of Cancer Medicine
Department of Thoracic/Head & Neck
Medical Oncology
The University of Texas M.D. Anderson
Cancer Center
Houston, TX 77030
- 2018 Elizabeth M. Jaffee, M.D.
The Dana and Albert "Cubby" Broccoli
Professor of Oncology
Co-Director of the Gastrointestinal Cancers
Program
Associate Director for Translational Research
The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins University
Baltimore, MD 21231
- 2018 Beth Y. Karlan, M.D.
Director, Women's Cancer Program
Samuel Oschin Comprehensive Cancer Institute
Director of Gynecologic Oncology
Department of Obstetrics & Gynecology
Cedar-Sinai Medical Center
Professor, Obstetrics and Gynecology
David Geffen School of Medicine, UCLA
Los Angeles, CA 90048

National Cancer Advisory Board (NCAB)

Membership and Term

2014 Mary Vaughan Lester
Board of Directors
University of California
San Francisco Foundation
Los Angeles, CA 99024

2014 H. Kim Lyerly, M.D.
Vice President/Global Head of Oncology
George Barth Geller Professor of Cancer Research
Professor of Surgery
Duke University School of Medicine
Durham, NC 27705

2016 Olufunmilayo I. Olopade, M.B.B.S., F.A.C.P.
Walter L. Palmer Distinguished Service
Professor of Medicine and Human Genetics
Associate Dean for Global Health
Director, Center for Clinical Cancer Genetics
University of Chicago
Pritzker School of Medicine
Chicago, IL 60637

2014 Jennifer A. Pietenpol, Ph.D.
Director
Vanderbilt-Ingram Cancer Center
B.F. Byrd, Jr. Professor of Oncology
Vanderbilt University Medical Center
Nashville, TN 37232

2018 Mack Roach III, M.D., F.A.C.R.
Professor of Radiation Oncology and Urology
Chair, Department of Radiation Oncology
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA 94143

2016 Johnathan M. Samet, M.D., M.S.
Professor and Flora L. Thornton Chair
Department of Preventative Medicine
Keck School of Medicine
Director, Institute for Global Health
University of Southern California
Los Angeles, CA

2018 Charles L. Sawyers, M.D.
Chairman
Human Oncology and Pathogenesis Program
Memorial Sloan-Kettering Cancer Center
Investigator, Howard Hughes Medical Institute
Professor of Medicine
Weill-Cornell Medical College
New York, NY 10065

2016 William R. Sellers, M.D.
Vice President/Global Head of Oncology
Novartis Institutes for BioMedical Research, Inc.
Cambridge, MA

Executive Secretary
Paulette S. Gray, Ph.D.

Committee Management Officer
Ms. Claire L. Harris

National Cancer Advisory Board (Continued)

Ex Officio Members

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S.
Director
National Institute of Environmental Health
Sciences and The National Technology Program
National Institutes of Health
Research Triangle Park, NC

Francis S. Collins, M.D., Ph.D.
Director
National Institutes of Health
Bethesda, MD

Margaret A. Hamburg, M.D.
Commissioner
Food and Drug Administration
Silver Spring, MD

John P. Holdren, Ph.D.
Science Advisor to the President
Director
Office of Science and Technology Policy
Executive Office of the President
Washington, DC

John Howard, M.D., M.P.H., J.D., LL.M.
Director
National Institute for Occupational Safety and Health
Washington, DC

Gina McCarthy, M.S.
Administrator
Environmental Protection Agency
Washington, DC

The Honorable Thomas E. Perez
Secretary
Department of Labor
Washington, DC

Robert A. Petzel, M.D.
Under Secretary for Health
Veterans Health Administration
Department of Veterans Affairs
Washington, DC

The Honorable Kathleen Sebelius, M.P.A.
Secretary
Department of Health and Human Services
Washington, DC

Inez Tenenbaum, M.Ed.
Chairman
Consumer Product Safety Commission
Bethesda, MD

Sharlene Weatherwax, Ph.D.
Associate Director, Office of Biological and
Environmental Research
Department of Energy
Washington, DC

Jonathan Woodson, M.D.
Assistant Secretary of Defense for Health Affairs
The Pentagon
Washington, DC

National Cancer Advisory Board (Continued)

Alternates to Ex Officio Members

Robert T. Anderson, Ph.D.
Director, Biological Systems Sciences Division
Office of Biological and Environmental Research
Office of Science
U.S. Department of Energy
Washington, DC
(Sharlene Weatherwax, Ph.D. - DOE)

Michael A. Babich, Ph.D.
Directorate for Epidemiology and Health Sciences
Consumer Product Safety Commission
Bethesda, MD
(Ms. Inez Tenenbaum- CPSC)

Patricia Bray, M.D., M.P.H.
Medical Officer, Office of Occupational Medicine
OSHA / Department of Labor
Washington, DC
(The Honorable Thomas E. Perez- DOL)

Vincent J. Cogliano, Ph.D.
Associate Director
Integrated Risk Information System Program
National Center for Environmental Assessment
Office of Research and Development
Environmental Protection Agency
Washington, DC
(Gina McCarthy, M.S. - EPA)

Michael Kelley, M.D., F.A.C.P.
National Program Director for Oncology
Veterans Health Administration
Department of Veterans Affairs
Durham, NC
(The Honorable Dr. Robert Petzel)

Aubrey Miller, M.D.
Senior Medical Officer
National Institute of Environmental Health Sciences
National Institutes of Health
Bethesda, MD
(Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S.- NIEHS)

Richard Pazdur, M.D., F.A.C.P.
Director, Office of Hematology Oncology Products
Center for Drug Evaluation and Research
Food and Drug Administration
Rockville, MD
(Margaret A. Hamburg, M.D. - FDA)

Craig D. Shriver, M.D., F.A.C.S., COL., M.C.
Chief, General Surgery Service
Program Director, National Capital Consortium
General Surgery
Principal Investigator, Clinical Breast Care Project
Professor of Surgery, Uniformed Services University
Walter Reed National Military Medical Center
Bethesda, MD
(Jonathan Woodson, M.D. - DHA)

Kerry Souza, Sc.D., M.P.H.
Epidemiologist
National Institute for Occupational Safety
and Health
Washington, DC
(John Howard, M.D., M.P.H., J.D., LL.M.- NIOSH)

Michael Stebbins, Ph.D.
Assistant Director, Biotechnology
Office of Science and Technology Policy
Executive Office of the President
Washington, DC
(John P. Holdren, Ph.D. -OSTP)

Lawrence A. Tabak, D.D.S., Ph.D.
Principal Deputy Director
National Institutes of Health
Bethesda, MD
(Francis S. Collins, M.D., Ph.D.)

Note: Bold print represents Ex Officio Members

NCI-Frederick Advisory Committee (NFAC)

Membership and Term

Chairperson

- 2016 Joe W. Gray, Ph.D.
Gordon Moore Endowed Chair
Chair, Department of Biomedical Engineering
Director, OHSU Center for Spatial Systems
Biomedicine
Oregon Health and Science University
Portland, OR
- 2014 J. Carl Barrett, Ph.D.
Vice-President
Translational Sciences Onc iMed
AstraZeneca
Waltham, MA 02451
- 2016 David Botstein, Ph.D.
Anthony B. Evnin Professor of Genomics
Department of Molecular Biology
Director
Lewis-Sigler Institute
Princeton University
Princeton, NJ 08544
- 2016 Vicki L. Colvin, Ph.D.
Vice-Provost
Kenneth S. Pitzer-Schlimberger
Professor of Chemistry
Rice University
Houston, TX 77005
- 2015 Levi A. Garraway, M.D., Ph.D.
Assistant Professor of Medicine
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA 02115
- 2015 Beatrice H. Hahn, M.D.
Professor of Medicine
Division of Hematology/Oncology
University of Pennsylvania
Philadelphia, PA 19104
- 2014 Monica J. Justice, Ph.D.
Head and Senior Scientist
Genetics & Genome Biology
The Hospital for Sick Children (SickKids)
Toronto, Ontario
- 2015 Lawrence J. Marnett, Ph.D.
Director
Vanderbilt Institute of Chemical Biology
Mary Geddes Stahlman Professor of Biochemistry,
Chemistry, and Pharmacology
Director, A.B. Hancock Jr. Memorial Laboratory
Director, Vanderbilt Institute of Chemical Biology
Vanderbilt University Medical Center
Nashville, TN 37232
- 2016 Jill P. Mesirov, Ph.D.
Chief Informatics Officer
Broad Institute of MIT and Harvard
Director
Computational Biology and Bioinformatics
Cambridge, MA 02142
- 2015 Garry P. Nolan, Ph.D.
Rachford and Carlota A. Harris Professor
Baxter Laboratory in Genetic Pharmacology
Department of Microbiology & Immunology
Director, Stanford University Proteomics Center
Stanford University
Stanford, CA 94305
- 2016 Kenneth J. Pienta, M.D.
The Donald S. Coffey Professor of Urology
Director, Urology Research Laboratories
Professor of Oncology
Professor of Pharmacology and
Molecular Sciences
Johns Hopkins Hospital
Brady Urological Institute
Baltimore, MD 21287

NCI-Frederick Advisory Committee (NFAC) (Continued)

Membership and Term

2014 Jennifer A. Pietsenpol, Ph.D.
Director
Vanderbilt-Ingram Cancer Center
B.F. Byrd, Jr. Professor of Oncology
Professor of Biochemistry
Vanderbilt University Medical Center
Nashville, TN 37232

2014 Steven T. Rosen, M.D., F.A.C.P.
Provost/Chief Scientific Officer
City of Hope
Duart, CA 91010

2015 Cheryl L. Willman, M.D.
Maurice and Marguerite Liberman
Distinguished Chair in Cancer Research
Director and CEO
Cancer Research and Treatment Center
University of New Mexico
Albuquerque, NM 87131

Executive Secretary
Thomas M. Vollberg, Sr., Ph.D.

Ex Officio Members

Stephen J. Chanock, M.D.
Director
Division of Cancer Epidemiology
and Genetics
National Cancer Institute
National Institutes of Health
Bethesda, MD

John Czajkowski, M.P.A.
Deputy Director for Management
National Cancer Institute
National Institutes of Health
Bethesda, MD

James H. Doroshow, M.D.
Deputy Director
Clinical and Translational Research
National Cancer Institute
National Institutes of Health
Bethesda, MD

Paulette S. Gray, Ph.D.
Director
Division of Extramural Activities
National Cancer Institute
National Institutes of Health
Bethesda, MD

Douglas R. Lowy, M.D.
Deputy Director
National Cancer Institute
National Institutes of Health
Bethesda, MD

Alan S. Rabson, M.D.
Deputy Director
National Cancer Institute
National Institutes of Health
Bethesda, MD

Craig W. Reynolds, Ph.D.
Associate Director
National Cancer Institute
Frederick National Laboratory for
Cancer Research
National Institutes of Health
Frederick, MD

Robert H. Wiltrot, Ph.D.
Director
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, MD

Clinical Trials and Translational Research Advisory Committee (CTAC)

Membership and Term

Chair

- 2015 James L. Abbruzzese, M.D., F.A.C.P.
Chief, Division of Medical Oncology
Associate Director, Clinical Research
Department of Medicine
Duke Cancer Institute
Duke University Medical Center
Durham, NC
- 2014 Susan G. Arbuck, M.D., M.Sc., F.A.C.P.
President
Susan G. Arbuck, M.D., LLC
Potomac, MD
- 2014 Monica M. Bertagnolli, M.D.
Professor of Surgery Harvard Medical School
Brigham & Women's Hospital
Dana-Farber Cancer Institute
Boston, MA
- 2014 Curt Civin, M.D. (BSA)
Associate Dean of Research
Professor of Pediatrics
Director
Center for Stem Cell Biology and Regenerative Medicine
University of Maryland School of Medicine
Baltimore, MD
- 2015 Kevin J. Cullen, M.D. (NCAB)
Director
University of Maryland Greenebaum Cancer Center
Baltimore, MD
- 2015 Nancy E. Davidson, M.D.
Director
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, PA
- 2015 J. Phillip Kuebler, M.D., Ph.D.
Principal Investigator
Columbus Community Clinical Oncology
Program (CCOP)
Columbus Oncology Associates, Inc.
Columbus, OH
- 2015 Scott M. Lippman, M.D.
Director, UC San Diego Moores Cancer Center
Senior Associate Dean and Associate Vice
Chancellor for Cancer Research and Care
Chugai Pharmaceutical Chair in Cancer Research
University of California, San Diego
La Jolla, CA
- 2014 Mary S. McCabe, R.N.
Director
Cancer Survivorship Program
Memorial Sloan Kettering Cancer Center
New York, NY
- 2016 Edith P. Mitchell, M.D., F.A.C.P.
Clinical Professor, Medicine and Medical Oncology
Program Leader, Gastrointestinal Oncology
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA
- 2016 Nikhil C. Munshi, M.D.
Associate Director
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA
- 2014 Lisa A. Newman, M.D., M.P.H., F.A.C.S.
Professor of Surgery
Director, Breast Care Center and
Multidisciplinary Breast Fellowship Program
Univ. of Michigan Comprehensive Cancer Center
Ann Arbor, MI
- 2014 Nancy A. Roach
Consumer Advocate
C3: Colorectal Cancer Coalition
Hood River, OR
- 2014 Peter G. Shields, M.D.
Deputy Director
Comprehensive Cancer Center
Professor
College of Medicine
The Ohio State University Medical Center
Columbus, OH
- 2015 George W. Sledge, Jr., M.D.
Chief
Division of Oncology
Stanford University
Stanford, CA
- 2016 Chris H.M. Takimoto, M.D., Ph.D., F.A.C.P.
Vice President
Translational Medicine Early Development
Janssen Pharmaceuticals, Inc.
Radnor, PA

Clinical Trials and Translational Research Advisory Committee (Continued)

Membership and Term

2014 Gillian M. Thomas, M.D., F.R.C.P.C., F.R.C.R.
Professor
Department of Radiation Oncology
Department of Obstetrics and Gynecology
University of Toronto
Odette Cancer Centre
Sunnybrook Health Sciences Centre
Toronto, Ontario
Canada

2014 Frank M. Torti, M.D., M.P.H. (BSA)
Executive Vice President for Health Affairs
University of Connecticut Health Center
Dean
University of Connecticut School of Medicine
Farmington, CT

2014 Miguel A. Villalona-Calero, M.D.
Division Director
Medical Oncology
Division of Hematology and Oncology
The Ohio State University
Columbus, OH

2015 George J. Weiner, M.D.
C.E. Block Chair of Cancer Research
Professor
Department of Internal Medicine
Director
Holden Comprehensive Cancer Center
Iowa City, Iowa

Executive Secretary
Sheila A. Prindiville, M.D., MPH

Ex Officio Members

James H. Doroshow, M.D.
Director
Division of Cancer Treatment and Diagnosis
National Cancer Institute
National Institutes of Health
Bethesda, MD

Paulette Gray, Ph.D.
Director
Division of Extramural Activities
National Cancer Institute
National Institutes of Health
Bethesda, MD

Rosemarie Hakim, Ph.D., M.S.
Epidemiologist
Centers for Medicare and Medicaid Services
Baltimore, MD

Lee Helman, M.D.
Chief
Pediatric Oncology Branch
Scientific Director for Clinical Research
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, MD

Michael J. Kelley, M.D., F.A.C.P.
National Program Director for Oncology
Veterans Health Administration
Department of Veterans Affairs
Washington, DC

Richard Pazdur, M.D., F.A.C.P.
Director
Office of Oncology Drug Products
Center for Drug Evaluation and Research
Food and Drug Administration
Silver Spring, MD

Alan Rabson
Deputy Director
National Cancer Institute
National Institutes of Health
Bethesda, MD

Subcommittees and Working Groups

NCI Clinical Trials Strategic Planning Ad Hoc Subcommittee
Pancreatic Cancer Working Group
CTAC Program Planning Working Group

Small Cell Lung Cancer Working Group
SPORE Program Evaluation Working Group

Subcommittee and Working Group Function Statements and membership can be found at
<http://deainfo.nci.nih.gov/advisory/ctac/workgroup/index.htm>

Board of Scientific Counselors Intramural Programs

Clinical Sciences and Epidemiology

Appointees	Expiration of Appointment	Appointees	Expiration of Appointment
Chair - Louis M. Weiner, M.D.	2017	Alexandra M. Levine, M.D.	2015
Edgar Ben-Josef, M.D.	2014	Sanford Markowitz, M.D., Ph.D.	2016
Jonine L. Bernstein, Ph.D.	2017	David A. Norris, M.D.*	2018
Arthur W. Blackstock, Jr., M.D.	2016	Augusto Ochoa, M.D.	2014
Tim Byers, M.D.	2015	Kenneth Offit, M.D.	2016
Nicola J. Camp, M.D., Ph.D.*	2013	Raphael E. Pollock, M.D., Ph.D.	2016
Susan Cohn, M.D.	2017	David Poplack, M.D.	2014
John F. Dipersio, M.D., Ph.D., F.A.C.P.*	2018	Jeremy Rich, M.D.	2017
Kojo S. J. Elenitoba-Johnson, M.D. *	2018	Thomas Rohan, M.D., Ph.D.	2014
Michael L. Freeman, Ph.D.	2018	Darryl K. Shibata, M.D.	2015
Marc T. Goodman, Ph.D.	2015	Walter Stadler, M.D.	2017
Nancy Goodman, J.D.	2018	Elizabeth Ward, Ph.D.	2014
Bernard Harlow, Ph.D.	2014	George Wilding, M.D.	2016
Carl June, M.D.	2014	Cheryl L. Willman, M.D.	2015
Karen L. Kelly, M.D.	2015		
Hongzhe Lee, Ph.D.	2016	Executive Secretary - Brian Wojcik, Ph.D.	

Basic Sciences

Chair - Joan W. Conaway, Ph.D.	2015	Robert E. Lewis, Ph.D.	2016
Lorena S. Beese, Ph.D.*	2018	Sergio Lira, M.D., Ph.D.	2018
Paul D. Bieniasz, Ph.D.	2014	Jonathan D. Licht, M.D.	2014
John C. Cambier, Ph.D.	2015	Ian G. Macara, Ph.D.	2014
Lawrence Corey, M.D.	2014	Roeland Nusse, Ph.D.	2017
Sara A. Courtneidge, Ph.D.	2016	Suzanne Ostrand-Rosenberg, Ph.D.	2014
Norman Drinkwater, Ph.D.	2014	Thomas L. Poulos, Ph.D.	2015
Errol Friedberg, M.D.	2014	Kenneth L. Rock, M.D.	2015
Joanna Groden, Ph.D.	2016	Daniel Romo, Ph.D.	2018
Daria J. Hazuda, Ph.D.	2015	James A. Wells, Ph.D.	2016
Eric Hunter, Ph.D.	2015	Tzzy-Chouu Wu, M.D., Ph.D.	2017
Stephen D. Hursting, Ph.D.	2017	Wayne M. Yokoyama, M.D.	2016
Alexandra L. Joyner, Ph.D.	2016	Virginia A. Zakian, Ph.D.	2015
Marcelo G. Kazanietz, Ph.D.	2015	Dong-Er Zhang, Ph.D.	2017
Brian C. Lewis, Ph.D.	2018		

Executive Secretary - Mehrdad Tondravi, Ph.D.

Board of Scientific Advisors Extramural Programs

Chair - Todd R. Golub, M.D.	2015	Joe W. Gray, Ph.D.	2016
Francis Ali-Osman, D.Sc.	2016	Chanita Hughes-Halbert, Ph.D.	2017
Kenneth C. Anderson, M.D., Ph.D.	2018	Joshua LaBaer, M.D., Ph.D.	2014
Dafna Bar-Sagi, Ph.D.	2018	Theodore S. Lawrence, M.D., Ph.D.	2016
Ethan M. Basch, M.D., M.Sc.	2017	Mr. Donald Listwin	2014
Sangeeta N. Bhatia, M.D., Ph.D.	2016	Maria E. Martinez, Ph.D., M.P.H.	2015
Andrea Califano, Ph.D.	2016	Luis F. Parada, Ph.D.	2016
Arul M. Chinnaiyan, M.D., Ph.D.	2015	Martine F. Roussel (Sherr), Ph.D.	2017
Curt I. Civin, M.D.	2015	Kevin M. Shannon, M.D.	2017
Graham A. Colditz, M.D., Dr.Ph.	2017	Mary L. Smith, J.D., M.B.A.	2017
Chi V. Dang, M.D., Ph.D.	2014	Lincoln Stein, M.D., Ph.D.	2016
Daniel A. DiMaio, M.D., Ph.D.	2017	Bruce W. Stillman, Ph.D.	2015
Jeffrey A. Drebin, M.D., Ph.D., F.A.C.S.	2014	Frank M. Torti, M.D., M.P.H.	2014
Brian J. Druker, M.D.	2016	Gregory L. Verdine, Ph.D.	2016
Karen M. Emmons, Ph.D.	2016	Cheryl L. Walker, Ph.D., A.T.S., F.A.A.N.*	2017
Betty Ferrell, Ph.D., RN, F.A.A.N.	2015	Irving L. Weissman, M.D.	2016
Kathleen M. Foley, M.D.	2015		
Stanton L. Gerson, M.D.	2016	Executive Secretary - Paulette S. Gray, Ph.D.	

* Newly appointed member pending personnel

President's Cancer Panel

Barbara K. Rimer, Dr.PH., M.P.H. 2014
Dean and Alumni Distinguished Professor
Gillings School of Global Public Health
The University of North Carolina at Chapel Hill
Chapel Hill, NC 27599

Owen N. Witte, M.D. 2014
Director
Eli and Edythe Broad Center of Regenerative Medicine
and Stem Cell Research
Investigator, Howard Hughes Medical Institute
University of California, Los Angeles
Los Angeles, CA 90095

Hill Harper, J.D. 2016
Cancer Survivor
4 Time New York Times Best-Selling Author, Actor,
and Philanthropist
Hollywood, CA

Abby B. Sandler, Ph.D.
Executive Secretary
NCI Office of the Director
9000 Rockville Pike
Bldg. 31, Room B2B37
Bethesda, MD 20892-2590

NCI Scientific Program Leaders (SPL) Members

Harold Varmus, M.D.
Director

Jeff Abrams, M.D.
Acting Director for Clinical Research, Division of
Cancer Treatment and Diagnosis
Associate Director, Cancer Therapy Evaluation
Program, DCTD

Stephen J. Chanock, M.D.
Director, Division of Cancer Epidemiology and
Genetics

Robert T. Croyle, Ph.D.
Director, Division of Cancer Control and Population
Sciences

John Czajkowski
Deputy Director, Management

James H. Doroshow, M.D.
Deputy Director, Clinical and Translational Research

Paulette S. Gray, Ph.D.
Director, Division of Extramural Activities

Peter Greenwald, M.D., Dr.Ph.
Associate Director, Prevention

Lee Helman, M.D.
Scientific Director, Clinical Research, CCR

Warren A. Kibbe, Ph.D.
Director, Center for Biomedical Informatics and
Information Technology

Barnett S. Kramer, M.D., M.P.H.
Director, Division of Cancer Prevention

Douglas Lowy, M.D.
Deputy Director

Alan S. Rabson, M.D.
Deputy Director

Dinah S. Singer, Ph.D.
Director, Division of Cancer Biology

Sanya A. Springfield, Ph.D.
Director, Center to Reduce Cancer Health Disparities

Louis M. Staudt, M.D.
Director, Center for Cancer Genomics

Joseph Tomaszewski, Ph.D.
Acting Director, Preclinical Research, Division of
Cancer Treatment and Diagnosis

Ted Trimble, M.D., M.P.H.
Director, Center for Global Health

Michael Weingarten
Director, SBIR Development Center

Linda Weiss, Ph.D.
Director, Cancer Centers

Jonathan Wiest, Ph.D.
Director, Center for Cancer Training

Robert H. Wiltout, Ph.D.
Director, Center for Cancer Research

Robert Yarchoan, M.D.
Director, Office of HIV & AIDS Malignancy

Joy Wiszniauckas
Executive Secretary

NCI Director's Consumer Liaison Group

Chair - Mr. Max Wallace Accelerate Brain Cancer Cure	2014	Mila McCurrach* The Lustgarten Foundation	2017
Mr. David Arons National Brain Tumor Society	2016	Dr. Michelle McMurry-Heath U.S. Food and Drug Administration	2014
Ms. Susan Braun The V Foundation for Cancer Research	2014	Mr. Jon Retzlaff American Association for Cancer Research	2014
Dr. Adam Clark U.S. Department of Health and Human	2015	Mr. Josh Sommer The Chordoma Foundation	2014
Ms. Joya Delgado Harris American Cancer Society	2015	Ms. Andrea Stern Ferris LUNGevity	2015
Ms. Martha Gaines* University of Wisconsin Law School	2017	Dr. Regina Vidaver* National Lung Cancer Partnership	2017
Ms. Linda House Cancer Support Community	2015		
Mr. Jeff Kaufman Adenoid Cystic Carcinoma Research Foundation	2015	Ms. Amy Bulman Executive Secretary	

*Pending Appointment

National Cancer Institute

Office of the Director
Harold Varmus, M.D.
Director
301-496-5615

**National Cancer
Advisory Board**
Executive Secretary
Dr. Paulette S. Gray
240-276-6340

President's Cancer Panel
Executive Secretary
Dr. Abby Sandler
301-496-7628

O-15

Center for Cancer Research
Director
Dr. Robert Wiltout
301-496-4345

**Division of Cancer Epidemiology
and Genetics**
Director
Dr. Stephen Chanock
240-276-7150

Division of Cancer Prevention
Director
Dr. Barnett Kramer
240-276-7120

**Division of Cancer Control
and Population Sciences**
Director
Dr. Robert Croyle
301-594-6776

**Division of Cancer Treatment
and Diagnosis**
Acting Directors
Dr. Jeff Abrams
Dr. Joe Tomaszewski

Division of Cancer Biology
Director
Dr. Dinah S. Singer
240-276-6180

Division of Extramural Activities
Director
Dr. Paulette S. Gray
240-276-6340

National Cancer Institute


Office of the Director


Harold Varmus, M.D.
Director
301-496-5615

Deputy Director
Dr. Alan Rabson
301-496-1927

Deputy Director
Dr. Doug Lowy
301-827-5699

Deputy Director
Clinical and Translational Research
Dr. Jim Doroshow
301-496-5615





Center for Biomedical Informatics and Information Technology

Vacant
Director
240-276-7000

Dr. George Komatsoulis
Deputy Director
240-276-7000

Infrastructure Branch

Director
Mr. Eric Williams
301-480-4210

Information Technology Branch

Director
Mr. Dwayne Forquer
240-246-5208

Informatics Operations Branch

Director
Mr. Anthony Kerlavage
240-276-5190

Resource Management Branch

Director
Mr. Daoud Meerzaman
240-276-5705

Office of Science Planning and Assessment

Acting Director
Dr. Margaret Ames
240-276-5738

Acting Deputy Director
Dr. James Corrigan
240-276-5734

Women's Health

Officer
Dr. Karen Parker
240-276-5735

Science Planning Branch

Acting Chief
Dr. Karen Parker
240-276-5735

Program Assessment Branch

Chief
Dr. James Corrigan
240-276-5734

Program Implementation Branch

Chief
Vacant

Office of Communications and Education

Acting Director
Ms. Nelvis Castro
240-276-6601

Associate Director
Ms. Nelvis C. Castro
240-276-6601

Multicultural and International Communications

Communications Technology Branch
Chief
Mr. Jonathan Cho
240-276-6551

Business Operations Branch
Chief
Mr. Kevin Davis
240-276-6498

Communications Planning and Coordination Branch
Acting Chief
Ms. Sabrina Islam-Raham
240-276-6534

Office of Cancer Content Management
Associate Director
Dr. Richard Manrow
240-276-6605

International Cancer Research Databank Branch
Acting Chief
Dr. Margaret Beckwith
240-276-6593




Cancer Publications Branch
Chief
Dr. Rebecca Chasan
240-276-6524

Office of Partnerships and Dissemination Initiatives
Acting Associate Director
Mr. Richard Manrow
240-276-6605

Office of Market Research and Evaluation
Acting Associate Director
Ms. Anita Ousley
240-276-6629

Office of Public Information and Resource Management
Associate Director
Ms. Mary Anne Bright
240-276-6647

Office of Communications Services
Associate Director
Mr. Kevin Davis
240-276-6498



Center for Strategic Scientific Initiatives

Acting Director
Dr. Doug Lowy
301-827-5699

Deputy Director
Dr. Jerry Lee
301-496-1045

**Office of Cancer
Nanotechnology Research**
Director
Dr. Piotr Grodzinski
301-451-8983

**Office of Cancer Clinical
Proteomics Research**
Director
Dr. Henry Rodriguez
301-451-8883

**Center to Reduce
Cancer Health Disparities**


Director
Dr. Sanya Springfield
240-276-6170

Deputy Director
Dr. H. Nelson Aguila
240-276-6161

Associate Deputy Director for Integration
Dr. Mary Ann Van Duyn
240-276-6165

**Disparities
Research Branch**
Chief
Vacant

Diversity Training Branch
Acting Chief
Dr. Peter Ogunbiyi
240-276-6176



**Center for Cancer Research
Office of the Director**

Director
Dr. Robert Wiltrott
301-496-4345

Scientific Director for Clinical Research
Dr. Lee Helman
301-496-4346

Office of the Clinical Director
Clinical Director
Dr. William Dahut
301-435-8183

Biostatistics and Data
Management Section
Chief
Dr. Seth Steinberg
240-276-5563

Dr. Jeffrey Strathern
Deputy Director
301-846-1274

Dr. Lawrence Samelson
Deputy Director
301-496-4346

**Cancer and Developmental
Biology Laboratory**
Chief
Dr. Alan Perantoni
301-846-6529

HIV Drug Resistance Program
Director
Dr. Stephen Hughes

**HIV DRP Retroviral Replication
Laboratory**
Chief
Dr. Stephen Hughes

Host Virus Interaction Branch
Acting Chief
Dr. Stephen Hughes
301-846-1619

**Cancer and Inflammation
Program**
Director
Dr. Giorgio Trinchieri

**Laboratory of Experimental
Immunology**
Chief
Dr. Giorgio Trinchieri
301-846-1323

**Laboratory of Molecular
Immunoregulation**
Chief
Dr. Joost Oppenheim
301-846-1551

**Laboratory of Cancer
Prevention**
Acting Chief
Dr. Jeffrey Strathern
301-846-1274

**Laboratory of Cell and
Developmental Signaling**
Chief
Dr. Debbie Morrison
301-846-1733

Molecular Discovery Program
Acting Director
Dr. Jeffrey Strathern
301-846-1274

Chemical Biology Laboratory
Chief
Dr. Joel Schneider
301-846-5954

Molecular Targets Laboratory
Chief
Dr. James McMahon
301-846-5391

**Structural Biophysics
Laboratory**
Chief
Dr. R. Andrew Byrd
301-846-1407

CCR Nanobiology Program
Chief
Dr. Robert Blumenthal
301-846-5532

**Laboratory of Protein
Dynamics and Signaling**
Chief
Dr. Allan Weissman
301-846-1222

**Macromolecular
Crystallography Laboratory**
Chief
Dr. Alexander Wlodawer
301-846-5036

**Mouse Cancer Genetics
Program**
Director
Dr. Lino Tessarollo
301-846-1202

**Laboratory of Genomic
Diversity**
Acting Chief
Dr. Jeffrey Strathern
301-846-1274

**Experimental Immunology
Branch**
Chief
Dr. Alfred Singer
301-496-5461

**Laboratory of Cancer Biology
and Genetics**
Co-Chiefs
Dr. Stuart Yuspa
301-496-2162
Dr. Glenn Merlino
301-496-4270

**Laboratory of Biochemistry
and Molecular Biology**
Chief
Dr. Shiv Grewal
301-594-6389

**Laboratory of Immune Cell
Biology**
Chief
Dr. Jonathan Ashwell
301-496-4931

Laboratory of Metabolism
Chief
Dr. Frank Gonzalez
301-435-5587

Vaccine Branch
Chief
Dr. Jay Berzofsky
301-496-6874
Clinical Component Deputy
Dr. Ron Gress
301-496-1791

Laboratory of Genome Integrity
Chief
Dr. Andre Nussenweig
301-435-6425

Basic Research Laboratory
Co-Chiefs
Dr. Lawrence Samelson
301-496-4346
Dr. Jeffrey Strathern
301-846-1274

**Laboratory of Receptor Biology
and Gene Expression**
Chief
Dr. Gordon Hager
301-496-9867

**Laboratory of Molecular
Biology**
Co - Chiefs
Dr. Ira Pastan
301-496-4797
Dr. Susan Gottesman
301-496-3524

Krietman Clinical
Component Deputy
Dr. Ron Gress
301-496-1791

**Division of Cancer Biology
Office of the Director**

Director
Dr. Dinah S. Singer
240-276-6180

Deputy Director
Dr. Dan Gallahan
240-276-6180

Associate Director
Dr. Cheryl Marks
240-276-6180

Associate Director
Dr. Suresh Mohla
240-276-6220

Associate Director
Dr. Larry Nagahara
301-451-3388

Cancer Etiology Branch
Chief
Dr. Don Blair
240-276-6190

**Tumor Biology and Metastasis
Branch**
Chief
Dr. Suresh Mohla
240-276-6220

**Cancer Immunology and Hematology
Branch**
Chief
Dr. R. Allan Mufson
240-276-6200

**DNA and Chromosome Aberrations
Branch**
Chief
Dr. Judith Mietz
240-276-6250

Cancer Cell Biology Branch
Chief
Dr. Barbara Spalholz
240-276-6230

**Structural Biology and Molecular
Applications Branch**
Chief
Dr. Jennifer Couch
240-276-6210

**Division of Cancer Epidemiology
and Genetics**

Office of the Director

Director
Dr. Stephen Chanock
240-276-7150

Deputy Director
Vacant

**Epidemiology and
Biostatistics Program**
Director

Dr. Robert N. Hoover
240-276-7412

**Office of Division
Operations and Analysis**
Chief

Ms. Marianne K. Henderson
240-276-7362

Office of Education
Chief

Dr. Jackie A. Lavigne
240-276-7237

**Human Genetics
Program**
Director

Dr. Margaret A. Tucker
240-276-7396

Biostatistics Branch

Chief
Dr. Nilanjan Chatterjee
240-276-7319

**Hormonal and Reproductive
Epidemiology Branch**

Chief
Dr. Louise A. Brinton
240-276-7296

Genetic Epidemiology Branch

Chief
Dr. Neil E. Caporaso
240-276-7228

Clinical Genetics Branch

Chief
Dr. Sharon Savage
240-276-7241

**Nutritional
Epidemiology Branch**

Chief
Vacant
240-276-7260

**Occupational and Environmental
Epidemiology Branch**

Chief
Dr. Debra T. Silverman
240-276-7174

**Laboratory of Translational
Genomics**

Chief
Vacant

**Radiation
Epidemiology Branch**

Chief
Dr. Martha S. Linet
240-276-7379

**Infections and
Immunoepidemiology Branch**

Chief
Dr. Allan Hildesheim
240-276-7101

Division of Cancer Prevention

Office of the Director

Director
Dr. Barnett Kramer
240-276-7120

Deputy Director
Dr. Lori Minasian
240-276-7120

Associate Director for Clinical Research
Dr. Leslie G. Ford
240-276-7110

Breast & Gynecologic Cancer Research Group
Chief
Dr. Mark Sherman
240-276-7010

Prostate & Urologic Cancer Research Group
Chief
Dr. Howard Parnes
240-276-7140

Lung & Upper Aerodigestive Cancer Research Group
Chief
Dr. Eva Szabo
240-276-7080

Gastrointestinal & Other Cancer Research Group
Chief
Dr. Asad Umar
240-276-7070

Chemopreventive Agent Development Research Group
Chief
Dr. Vernon Steele
240-276-7030

Community Oncology and Prevention Trials Research Group
Chief
Dr. Wortia McCaskill-Stevens
240-276-7050

Nutritional Science Research Group
Acting Chief
Dr. Harold Seifried
240-276-7090

Basic Prevention Science Research Group
Acting Chief
Dr. Barnett Kramer
240-276-7120

Cancer Biomarkers Research Group
Chief
Dr. Sudhir Srivastava
240-276-7040

Early Detection Research Group
Acting Chief
Dr. Paul Pinsky
240-276-7060

Protocol Information Office
Head
Ms. Anne Tompkins
240-276-7076

Biometry Research Group
Acting Chief
Dr. Victor Kipnis
240-276-7020

Cancer Prevention Fellowship Program
Director
Dr. David Nelson
240-276-5647

Division of Cancer Control and Population Sciences

Office of the Director

Director

Dr. Robert Croyle
240-276-6690

Deputy Director
Dr. Deborah Winn
240-276-6690

Implementation Science
Acting Deputy Director
Dr. Cynthia Vinson
240-276-6745

Senior Advisor for
Cancer Surveillance
Dr. Brenda Edwards
240-276-6722

Office of Cancer Survivorship
Director
Dr. Julia Rowland
240-276-6827

Epidemiology and Genomics Research Program
Acting Associate Director
Dr. Muin Khoury
240-276-6888

Methods and Technologies Branch
Chief
Dr. Mukesh Verma
240-276-6889

Modifiable Risk Factors Branch
Chief
Dr. Britt Reid
240-276-6725

Host Susceptibility Factors Branch
Chief
Dr. Elizabeth Gillanders
240-276-6764

Clinical and Translational Epidemiology Branch
Chief
Dr. Andrew Freedman
240-276-6697

Behavioral Research Program
Associate Director
Dr. William Klein
240-276-6972

Process of Care Research Branch
Chief
Dr. Stephen Taplin
240-276-6947

Basic Biobehavioral and Psychological Sciences Branch
Chief
Dr. Paige Green McDonald
240-276-6899

Health Communication and Informatics Research Branch
Chief
Dr. Bradford Hesse
240-276-6721

Health Behaviors Research Branch
Chief
Dr. Linda Nebeling
240-276-6855

Tobacco Control Research Branch
Chief
Dr. Michele Bloch
240-276-6878

Science of Research and Technology Branch
Chief
Dr. William Riley
240-276-6973

Applied Research Program
Associate Director
Dr. Rachel Ballard-Barbash
240-276-6909

Health Services and Economics Branch
Chief
Dr. Ann Geiger
240-276-6995

Outcomes Research Branch
Acting Chief
Dr. Neeraj Arora
240-276-6895

Risk Factor Monitoring and Methods Branch
Chief
Dr. Susan Krebs-Smith
240-276-6949

Surveillance Research Program
Associate Director
Dr. Lynne Penberthy
240-276-6740

Surveillance Systems Branch
Acting Chief
Dr. Zaria Tatalovich
240-276-6976

Data Analysis and Interpretation Branch
Chief
Dr. Kathleen Cronin
240-276-6836

Data Modeling Branch
Chief
Dr. Angela Mariotto
240-276-6698

Statistical Methodology and Applications Branch
Chief
Dr. Eric Feuer
240-276-6772

Division of Cancer Treatment and Diagnosis

Office of the Director

Acting Directors

Dr. Jeff Abrams
240-276-6515

Dr. Joseph Tomaszewski
301-496-6711

Biometrics Research Branch
Chief
Dr. Richard Simon
240-276-6028

Developmental Clinical Trials and Preclinical Studies
Acting Section Chief
Dr. Richard Simon
240-276-6028

Clinical Trials Section
Acting Section Chief
Dr. Richard Simon
240-276-6028

Molecular Statistics and Bioinformatics Section
Acting Section Chief
Dr. Richard Simon
240-276-6028

Office of Cancer Complementary and Alternative Medicine
Associate Director
Dr. Jeffrey White
240-276-6040

Translational Research Program
Associate Director
Dr. Toby T. Hecht
240-276-5683

Radiation Research Program
Associate Director
Dr. C. Norman Coleman
240-276-5690

Radiotherapy Development Branch
Chief
Dr. Eric Bernhard
240-276-5704

Molecular Radiation Therapeutics Branch
Chief
Vacant
240-276-5697

Clinical Radiation Oncology Branch
Chief
Dr. Bhadransain Vikram
240-276-5690

Cancer Therapy Evaluation Program
Associate Director
Dr. Jeffrey Abrams
240-276-6515

Investigational Drug Branch
Chief
Dr. James Zwiebel
240-276-6108

Clinical Investigations Branch
Chief
Dr. Margaret Mooney
240-276-6086

Pharmaceutical Management Branch
Chief
Mr. Charles Hall
240-276-6056

Regulatory Affairs Branch
Chief
Dr. Jan Casadei
240-276-6125

Clinical Trials Monitoring Branch
Chief
Mr. Gary Smith
240-276-6074

Clinical Grants and Contracts Branch
Chief
Dr. Roy Wu
240-276-6140

Clinical Trials Operations and Informatics Branch
Chief
Mr. Steven Friedman
240-276-6138

Developmental Therapeutics Program
Associate Director
Dr. Jerry M. Collins
240-276-5949

Deputy Associate Director
Dr. James Crowell
240-276-5903

Information Technology Branch
Chief
Dr. Daniel Zaharevitz
240-624-1261

Biological Testing Branch
Chief
Dr. Melinda Hollingshead
301-846-5065

Biological Resources Branch
Chief
Dr. Stephen Creekmore
301-846-1100

Toxicology and Pharmacology Branch
Chief
Dr. Myrtle Davis
240-276-5915

Molecular Pharmacology Branch
Chief
Dr. Beverly Teicher
240-276-5972

Screening Technologies Branch
Acting Chief
Dr. James Crowell
240-276-5903

Natural Products Branch
Chief
Dr. David Newman
301-624-1274

Drug Synthesis and Chemistry Branch
Chief
Dr. Joel Morris
240-276-5953

Grants & Contracts Operations Branch
Chief
Dr. Mary Wolpert-DeFilippes
240-276-5977

Pharmaceutical Resources Branch
Chief
Dr. Rao Vishnuvajjala
240-276-5962

Cancer Diagnosis Program
Associate Director
Dr. Barbara Conley
240-276-5680

Diagnostics Evaluation Branch
Chief
Dr. John Jessup
240-276-5952

Pathology Investigations and Resources Branch
Chief
Dr. Irina Lubensky
240-276-6490

Diagnostic Biomarkers and Technology Branch
Branch Chief
Dr. James Tricoli
240-276-5725

Biorepositories and Biospecimen Research Branch
Acting Branch Chief
Dr. Helen Moore
240-276-5713

Cancer Imaging Program
Associate Director
Dr. Paula Jacobs
240-276-5950

Deputy Associate Director
Vacant

Diagnostic Imaging Branch
Chief
Dr. Lalitha Shankar
240-276-5936

Molecular Imaging Branch
Acting Chief
Dr. Paula Jacobs
240-276-59650

Image-Guided Intervention Branch
Acting Chief
Dr. Laurence Clarke
240-276-5956

Imaging Technology Development Branch
Chief
Dr. Laurence Clarke
240-276-5956

Division of Extramural Activities

Office of the Director

Director
Dr. Paulette S. Gray
240-276-6340

Deputy Director
Vacant
240-276-6340

Assistant Director
Dr. Peter Wirth
240-276-6434

Office of Extramural Applications

Associate Director
Dr. Amir Sahar-Khiz
240-276-6412

Program and Review Extramural Staff Training Office

Chief
Dr. Michael Small
240-276-6438

Office of Referral, Review and Program Coordination

Associate Director
Dr. Shamala Srinivas
240-276-6430

Applied Information Systems Branch

Chief
Mr. Greg Fischetti
240-276-6413

Research Analysis and Evaluation Branch

Chief
Ms. Marilyn R. Gaston
240-276-6423

Research Programs Review Branch

Chief
Dr. Caron Lyman
240-276-6348

Program Coordination and Referral Branch

Chief
Dr. Christopher L. Hatch
240-276-6454

Resources and Training Review Branch

Chief
Dr. Robert E. Bird
240-276-6344

Special Review and Logistics Branch

Acting Chief
Dr. Shamala Srinivas
240-276-6430

Links to Cancer Statistics

SOURCES:

Annual Report to the Nation on the Status of Cancer, 1975-2010

This report provides an annual update of cancer incidence, mortality, and trends in the United States. The Centers for Disease Control and Prevention, the American Cancer Society, the National Cancer Institute, and the North American Association of Central Cancer Registries have collaborated since 1998 to create the Annual Report to the Nation on the Status of Cancer. The current report, published online in December 2013, features the prevalence of comorbidity and its impact on survival among persons with lung, colorectal, breast, or prostate cancer.

http://seer.cancer.gov/report_to_nation/

Fast Stats

Interactive tool providing tables, charts, and graphs with information related to incidence, mortality, survival and stage, prevalence, and lifetime risk (probability of developing or dying from cancer).

<http://seer.cancer.gov/faststats/>

SEER Cancer Statistics Review, 1975-2010

The SEER Cancer Statistics Review (CSR), is published annually by the Data Analysis and Interpretation Branch of the NCI. The scope and purpose of this work are consistent with a report to the Senate Appropriations Committee (Breslow, 1988) which recommended that a broad profile of cancer be presented to the American public on a routine basis. This edition includes statistics from 1975 through 2010, the most recent year for which data are available.

http://seer.cancer.gov/csr/1975_2010

Cancer Stat Fact Sheets

Collection of statistical summaries for a number of common cancer types, with information related to incidence, mortality, survival, stage, prevalence, and lifetime risk.

<http://seer.cancer.gov/statfacts/>

Cancer Prevalence and Cost of Care Projections

This site is based on a study that estimates and projects the national cost of cancer care through the year 2020 separately for multiple cancer sites using the most recent available U.S. population projections, cancer incidence, survival, and cost of care data.

<http://costprojections.cancer.gov/index.html>

REPORTS:

Costs of Cancer Care, 2011/2012

http://progressreport.cancer.gov/doc_detail.asp?pid=1&did=2011&chid=105&coid=1026&mid=

Leading Causes of Death in the United States, 1975 and 2010

http://seer.cancer.gov/csr/1975_2010/results_merged/topic_lead_cod.pdf

Estimated New Cancer Cases and Deaths for 2013

http://seer.cancer.gov/csr/1975_2010/results_merged/sect_01_overview.pdf

Person-Years of Life Lost Due to Cancer and Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2010

http://seer.cancer.gov/csr/1975_2010/results_merged/topic_year_lost.pdf

Incidence, Mortality, and Five-Year Relative Survival Rates by Cancer Site

http://seer.cancer.gov/csr/1975_2010/results_merged/topic_survival.pdf

Annual Percent Change in Incidence and Mortality Rates, 2001-2010

http://seer.cancer.gov/csr/1975_2010/results_merged/topic_graph_trends.pdf

Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity

http://seer.cancer.gov/csr/1975_2010/results_merged/topic_topfifteen.pdf

Age-Adjusted U.S. Death Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity

http://seer.cancer.gov/csr/1975_2010/results_merged/topic_mor_trends.pdf

Prevalence of Cancer: Estimated Number of Persons Diagnosed with Cancer, 5- and 32-Year Limited Duration

http://seer.cancer.gov/csr/1975_2010/results_merged/topic_prevcounts.pdf

Fiscal Year 2013 Budget

(Dollars in Thousands)

A. Actual Obligations Resulting From Appropriated Funds:

FY 2013 Appropriation (Continuing Resolution)	\$5,072,183
Rescission	-10,144
Transfer under the HHS Secretary's transfer authority	-28,044
Sequestration	-254,589
Transfers from National Children's Study and NIH Office of AIDS Research	9,714
Lapse	-106
Actual Obligations Subtotal	\$4,789,014

B. Reimbursable Obligations:

\$36,779


C. Total NCI Obligations:

\$4,825,793 *

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as royalty income (see page B-7).

Program Structure Fiscal Year 2013

(Dollars in Thousands)




Budget Activity	Amount	Percent
Research:		
Cancer Causation	\$1,180,381	24.6%
Detection and Diagnosis Research	402,592	8.4%
Treatment Research	1,072,018	22.4%
Cancer Biology	713,561	14.9%
Subtotal Research	3,368,552	70.3%
Resource Development:		
Cancer Centers Support	510,984	10.7%
Research Manpower Development	169,022	3.5%
Buildings and Facilities	7,904	0.2%
Subtotal Resource Development	687,910	14.4%
Cancer Prevention and Control	295,121	6.2%
Program Management and Support	437,431	9.1%
*Total NCI	\$4,789,014	100.0%

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as Royalty income (see page B-7).

Extramural Funds Fiscal Year 2013

(Dollars in Thousands)



Mechanism	Amount	Percent
Contracts:		
Research & Development (R&D) Contracts	\$616,046	17.1%
Buildings and Facilities	7,904	0.2%
Construction Contracts	0	0.0%
Subtotal Contracts	623,950	17.3%
Grants:		
Research Project Grants (RPGs)	2,000,161	55.4%
Cancer Centers/Specialized Centers/SPORES	533,951	14.8%
NRSA	65,788	1.8%
Other Research Grants	387,538	10.7%
Construction Grants	0	0.0%
Subtotal Grants	2,987,438	82.7%
Total Extramural Funds	3,611,388	100.0%
Total Intramural/RMS	1,177,626	
*Total NCI	\$4,789,014	

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as Royalty income (see page B-7).

NCI Obligations by Mechanism, Fiscal Year 2013

(Dollars in Thousands)

		Number	Amount	% of Total	
RPGs	Non-Competing	3,562	\$1,486,513	31.0%	
	Administrative Supplements	214	38,444	0.8%	
	Competing	1,095	403,945	8.4%	
	Subtotal, without SBIR/STTR Grants	4,657	1,928,902	40.3%	
	SBIR/STTR Grants	159	71,260	1.5%	
	Subtotal, RPGs	4,816	2,000,162	41.8%	
Centers & SPOREs	Cancer Centers Grants-P20/P30	82	262,232	5.5%	
	SPOREs-P50	54	104,296	2.2%	
	Other P50s/P20s	13	21,467	0.5%	
	Other Specialized Centers	112	145,956	3.1%	
	Subtotal, Centers	261	533,951	11.2%	
Other Research	Career Program				
	Temin & Minority Mentored Awards-K01	51	6,531	0.1%	
	Estab. Inv. Award-K05	19	2,743	0.1%	
	Preventive Oncology-K07	63	9,419	0.2%	
	Clinical Investigator-K08	100	16,094	0.3%	
	Clinical Oncology-K12	18	12,763	0.3%	
	Stem Cell Research-K18	0	0	0.0%	
	Transitional Career Development-K22	21	3,562	0.1%	
	Mentored Patient Oriented RCDA-K23	35	5,823	0.1%	
	Mid-Career Invest. & Patient Orient. Res-K24	15	2,599	0.1%	
	Mentored Quant. Res Career-K25	15	2,061	0.0%	
	Pathway to Independence Awards-K99	50	5,930	0.1%	
	Subtotal, Career Program	387	67,525	1.4%	
	Cancer Education Program-R25	96	34,466	0.7%	
	Clinical Cooperative Groups-U10	120	235,447	4.9%	
	Minority Biomedical Support-S06	4	376	0.0%	
	Rsch Enhance-SC1 & Pilot Research - SC2	0	0	0.0%	
	Continuing Education	1	88	0.0%	
	Resource Grants-R24/U24	97	48,776	1.0%	
	Explor Coop Agreement-U56	0	0	0.0%	
	Global Infect. Disease Rsrch Training Prog - D43	0	0	0.0%	
	Conference Grants-R13	0	861	0.0%	
	Subtotal, Other Research Grants	705	387,539	8.1%	
	Subtotal, Research Grants		5,782	2,921,652	61.0%
	NRSA Fellowships	<i>Trainees:</i>	1,359	65,787	1.4%
	R&D Contracts	R&D Contracts	367	577,169	12.1%
		SBIR Contracts	66	38,877	0.8%
Subtotal, Contracts		433	616,046	12.9%	
Intramural Research	Program	1,863	640,534	13.4%	
	NIH Management Fund/SSF Assessment		171,038	3.6%	
	Subtotal, Intramural Research	<i>FTEs:</i>	1,863	811,572	17.0%
RMS	Research Management and Support (RMS)	1,240	300,997	6.3%	
	NIH Management Fund/SSF Assessment		65,056	1.4%	
	Subtotal, RMS	<i>FTEs:</i>	1,240	366,053	7.6%
Buildings and Facilities			7,904	0.2%	
Construction			0	0.0%	
*Total NCI	<i>FTEs:</i>	3,103	\$4,789,014	100.0%	

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as Royalty income (see page B-7).


Division Obligations by Mechanism, Fiscal Year 2013

(Dollars in Thousands)

CCR	DCEG	DCTD	DCB	DCCPS	DCP	DEA	OD	Research Grants	Program Support
								1,411,156	75,357
								38,444	
								403,945	
								1,853,545	75,357
								71,260	
								1,924,805	75,357
							262,232		
		103,866					430		
		9,354		11,555	388		170		
		2,290	33,192	15,753	2,484		92,237		
		115,510	33,192	27,308	2,872		355,069		
							6,531		
							2,743		
							9,419		
							16,094		
							12,763		
							0		
							3,562		
							5,823		
							2,599		
							2,061		
							5,930		
							67,525		
							34,466		
		149,614			84,763		1,067	3	
								376	
								88	
								48,776	
								861	
		149,614			84,763		35,533	50,104	
		265,124	33,192	27,308	87,635		458,127	1,974,909	75,357
							65,787		
	17,850	130,301		64,944	44,125		210,036		109,913
							38,877		
	17,850	130,301		64,944	44,125		248,913		109,913
389,517	66,044						182,620		2,353
									171,038
389,517	66,044						182,620		173,391
		46,861	9,287	30,236	21,686	21,842	163,208		7,877
									65,056
		46,861	9,287	30,236	21,686	21,842	163,208		72,933
							7,904		
\$389,517	\$83,894	\$442,286	\$42,479	\$122,488	\$153,446	\$21,842	\$1,126,559	\$1,974,909	\$431,594

NIH Management Fund, Service & Supply Fund, and GSA Rent Fiscal Year 2013

(Dollars in Thousands)



DISTRIBUTION OF NCI PAYMENT	Amount	Share of NCI
Clinical Center	\$113,390	46.9%
Center for Scientific Review	12,912	5.3%
Center for Information Technology	5,833	2.4%
Service and Supply Fund Assessment	82,088	33.9%
Other Research Services	13,862	5.7%
Other OD	13,842	5.7%
Total Management Fund and SSF	241,927	100.0%
Other NIH Institutes Management Fund and SSF	1,346,749	
Total NIH Management Fund and SSF	\$1,588,676	

The Management Fund provides for the financing of certain common research and administrative support activities which are required in the operations of NIH:

Clinical Center: Admissions and follow-up, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition services, housekeeping services, laundry, and social work.

Center for Scientific Review: Initial scientific review of applications and assignment of research grant applications to institutes.

Center for Information Technology: Research and development program in which concepts and methods of computer science are applied to biomedical problems.

GSA Rental Payments for Space: All building rental costs, including utilities and guard services.

Other Research Services: Procurement, safety, engineering, biomedical engineering, veterinary resources, and library services.

Service & Supply Fund: Mainframe computing, enterprise IT software planning and development, engineering planning and design, printing, telecommunications, procurement, shipping and receiving, motor pool, research animals, fabrication and maintenance of scientific equipment, utilities and plant maintenance, and biomedical engineering.

Special Sources of Funds

CRADAs

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Licensing agreements are usually incorporated into the CRADA document which addresses patent rights attributable to research supported under the CRADA.

NCI CRADA Receipts Deposited to the U.S. Treasury
(Dollars in Thousands)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
2003	11,533	5,221	5,361
2004	11,351	5,080	5,469
2005	10,962	6,858	4,253
2006	13,567	6,142	7,125
2007	12,584	9,410	8,360
2008	13,634	6,677	7,200
2009	13,111	5,466	4,765
2010	13,813	5,024	5,644
2011	13,150	8,582	5,894
2012	15,504	9,253	5,668
2013	10,587	11,226	8,470

Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to support employees of the laboratory, further scientific exchange, and provide education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts at NCI and NIH.

NCI Royalty Income Funding History
(Dollars in Thousands)

Years	Collections*	Inventor	
		Payments	Other
2003/2005	27,271	5,262	22,009
2004/2006	26,923	4,950	21,973
2005/2007	34,086	5,745	28,341
2006/2008	29,811	6,853	22,958
2007/2009	36,344	7,210	29,134
2008/2010	50,269	8,192	42,077
2009/2011	51,621	10,225	41,396
2010/2012	58,515	5,729	52,786
2011/2013	69,155	23,271	45,884
**2012/2014	73,060	14,766	58,294
**2013/2015	91,324	14,649	76,675

*Does not include assessments by NIH.

**2012/2014 and 2013/2015 payments are estimates.

Stamp Out Breast Cancer

The Stamp Out Breast Cancer Act (PL 105-41) was established in August 1997, extended in July 2000 (PL 106-253), November 2005 (PL 109-100), December 2007 (PL 110-150), and again in December 2011 (PL 112-80). This act allows postal customers to contribute funding to breast cancer research through their voluntary purchases of special rate postage stamps from the U.S. Postal Service (USPS). Of the funds collected above the postage costs and administrative costs, the Act requires the USPS to transfer 70% to NIH and 30% to the Department of Defense. As of September 2013, NCI has received \$53,916,198. NCI has used these funds for research projects directed towards breast cancer research. Thus far, four major programs have been funded, including the Insight Awards to Stamp Out Breast Cancer, the Breast Cancer Research Stamp Exception Program, the Breast Cancer Premalignancy Program, and a clinical trial to determine the risk of breast cancer recurrence. In FY 2013, \$1.337 million was obligated on Breast Cancer Stamp Fund programs.

Funding for Research Areas

(Dollars in Millions)

The National Cancer Institute reports how appropriated funds are spent based on different categories or classifications, including specific cancer sites, cancer types, diseases related to cancer, as well as types of NCI research mechanisms. The table below identifies funding levels for frequently requested areas of cancer research.

The research areas in this table do not represent the entire NCI research portfolio. Moreover, funding for research areas often overlap, and therefore the total for all research areas does not add to the total NCI budget. For example, funding for a clinical trial on breast cancer would be included in both the Breast Cancer and the Clinical Trials lines in the table below. Similarly, a basic cancer research project may be relevant to cervical, uterine, and ovarian cancers, and relevant amounts would be included in the amounts for all three areas of cancer research.

Disease Area	2009 Actual	2010 Actual	2011 Actual	2012 Actual	2013 Actual
Total NCI Budget	\$4,966.9	\$5,098.1	\$5,058.1	\$5,067.3	4,789.0
AIDS	265.9	272.1	270.0	271.7	261.6
Brain & CNS	151.5	156.8	172.6	177.5	176.8
Breast Cancer	599.5	631.2	625.1	602.9	559.2
Cervical Cancer	77.8	77.0	81.4	72.6	63.4
Clinical Trials	846.6	852.3	877.8	752.8	676.5
Colorectal Cancer	264.2	270.4	265.1	256.3	238.3
Head and Neck Cancers	77.1	62.7	61.8	71.1	57.6
Hodgkin Disease	18.2	14.6	13.4	15.6	14.5
Leukemia	220.6	239.7	227.0	234.7	234.9
Liver Cancer	70.3	72.6	66.2	64.6	64.0
Lung Cancer	246.9	281.9	296.8	315.1	285.9
Melanoma	103.7	102.3	115.6	121.2	122.5
Multiple Myeloma	45.2	48.5	54.9	61.3	45.4
Non-Hodgkin Lymphoma	130.9	122.4	126.4	119.5	113.7
Ovarian Cancer	110.1	112.3	110.8	111.7	100.6
Pancreatic Cancer	89.7	97.1	99.5	105.4	101.9
Prostate Cancer	293.9	300.5	288.3	265.1	255.6
Stomach Cancer	15.4	14.5	13.4	12.1	11.2
Uterine Cancer	18.0	14.2	15.9	19.1	17.8

Note: These figures were created using NCI's coding methodology. More information about this methodology, as well as the research projects associated with these and other disease area categories, are available on the NCI Funded Research Portfolio website.

<http://fundedresearch.cancer.gov/>

FY 2013 funds available to the NCI totaled \$4.789 billion, reflecting a decrease of 5.5 percent, or \$278 million from the previous fiscal year. Under the NCI RPG funding policy for FY 2013, non-competing grants were awarded with a 6 percent reduction from the committed level. For more information on NCI's grant funding policy, visit the NCI Division of Extramural Affairs website.

<http://deainfo.nci.nih.gov/index.htm>

Research Project Grants (RPGs) Summary, Fiscal Years 2012-2013

About half of competing dollars supported grants awarded within the established payline and RFAs and half supported grants as an exception to the fundable range.

RFA funds accounted for 8.9% of the FY 2013 competing dollars.


A total of 1,095 competing RPGs were funded.

RPGs*				
(Dollars in Thousands)				
	2012		2013	
	No. or %	Amount	No. or %	Amount
RPG Awards Funded				
Total Funding for RPGs	5,021	\$2,150,624	4,816	\$2,000,161
SBIR/STTR	190	77,355	159	71,260
Funding for RPGs without SBIR/STTR Program	4,831	2,073,268	4,657	1,928,902
Continuation or Noncompeting Grants Funded	3,746	1,659,264	3,562	1,411,156
Competing Grants Funded	1,085	414,004	1,095	403,945
Administrative Supplements	184	19,819	214	38,444
Partial assessment for DHHS Program Evaluation		75,329		75,357
Funds Set Aside within Competing Dollars for:				
Grants within Paylines:	574	174,255	663	196,720
Traditional R01	352	136,052	354	139,613
RFA Grants	88	41,677	82	35,925
Share of Competing Grant Funds	10.1%		8.9%	
Exception Grants	482	228,534	432	207,224
Share of Competing Grant Funds	55.2%		51.3%	
Competing RPGs				
Total Competing Application Requests**	8,014		7,974	
Funding Success Rate	13.5%		13.7%	
Percentile Funding for R01 grants	7th		9th	
Average Cost-Competing	\$382		\$369	
Average Reduction from Recommended/Requested	-17%		-17%	

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.

**EXCLUDES SBIR/STTR.

RPGs Number of Awards Fiscal Years 2004-2013



Includes Small Business Innovation Research and Small Business Technology Transfer Awards.
EXCLUDES projects awarded with Stamp Out Breast Cancer funds.

RPGs Requested, Awarded, and Success Rate Fiscal Years 2004-2013

(Dollars in Thousands. Includes Small Business Innovation Research and Small Business Technology Transfer Awards.)

Fiscal Year	Type		Requested		Awarded		Success
2004	Competing	New	6,558	\$2,045,451	1,333	\$339,925	23.6%
		Renewal	988	518,201	445	210,790	
		Supplement	24	8,337	7	2,196	
		Subtotal	7,570	2,571,989	1,785	552,911	
	Non-Competing				3,682	1,549,727	
	Total				5,467	\$2,102,638	
2005	Competing	New	6,357	\$2,239,503	1,086	\$309,507	19.2%
		Renewal	1,050	473,898	335	162,857	
		Supplement	22	6,147	7	1,185	
		Subtotal	7,429	2,719,548	1,428	473,549	
	Non-Competing				3,984	1,656,614	
	Total				5,412	\$2,130,164	
2006	Competing	New	6,585	\$2,215,548	1,105	\$293,912	19.2%
		Renewal	984	542,799	348	170,110	
		Supplement	13	4,098	2	681	
		Subtotal	7,582	2,762,445	1,455	464,703	
	Non-Competing				3,980	1,633,442	
	Total				5,435	\$2,098,145	
2007	Competing	New	6,428	\$2,116,286	1,178	\$306,431	20.2%
		Renewal	864	482,655	295	163,225	
		Supplement	12	3,513	2	609	
		Subtotal	7,304	2,602,454	1,475	470,265	
	Non-Competing				3,997	1,582,828	
	Total				5,472	\$2,053,093	
2008	Competing	New	5,944	\$1,991,089	1,150	\$324,070	21.7%
		Renewal	966	515,784	352	187,458	
		Supplement	1	408	1	338	
		Subtotal	6,911	2,507,281	1,503	511,866	
	Non-Competing				3,877	1,509,611	
	Total				5,380	\$2,021,477	
2009	Competing	New	6,167	\$2,069,518	1,029	\$320,980	19.4%
		Renewal	1,000	500,201	358	177,853	
		Supplement	5	1,141	1	67	
		Subtotal	7,172	2,570,860	1,388	498,900	
	Non-Competing				3,791	1,564,139	
	Total				5,179	\$2,063,039	
2010	Competing	New	7,494	\$2,776,315	1,041	\$375,830	16.3%
		Renewal	1,007	591,060	343	183,675	
		Supplement	18	6,805	3	1,491	
		Subtotal	8,519	3,374,180	1,387	560,996	
	Non-Competing				3,692	1,531,733	
	Total				5,079	\$2,092,729	
2011	Competing	New	8,445	\$3,183,607	962	\$342,196	12.6%
		Renewal	756	454,907	201	104,002	
		Supplement	29	8,871	3	460	
		Subtotal	9,230	3,647,385	1,166	446,658	
	Non-Competing				3,853	1,641,694	
	Total				5,019	\$2,088,352	
2012	Competing	New	8,414	\$3,220,278	1,020	\$351,601	13.4%
		Renewal	644	397,473	197	103,990	
		Supplement	25	9,860	3	594	
		Subtotal	9,083	3,627,611	1,220	456,185	
	Non-Competing				3,801	1,619,109	
	Total				5,021	\$2,075,294	
2013	Competing	New	8,191	\$2,964,897	1,017	\$342,519	13.6%
		Renewal	615	350,678	178	95,545	
		Supplement	6	1,649	0	0	
		Subtotal	8,812	3,317,224	1,195	438,064	
	Non-Competing				3,621	1,486,740	
	Total				4,816	\$1,924,804	


Success rate is the number of awarded grants divided by the number of awards requested.

Totals exclude Assessments for Program Evaluation and projects awarded with Stamp Out Breast Cancer Funds.

RPGs Awards by Grant Activity Codes Fiscal Years 2004-2013

(Dollars in Thousands. Descriptions of the NIH Activity Codes appear on the next page)

		R01	DP1	DP2	DP5	P01	R00	R37	R29	RFA	U01	U19	UH2	UM1	R03	R21	R33	R15	R55	R56	SBIR/ STTR	TOTAL
2004	No.	3,780				177		73	0	233	26				240	425	96	20			397	5,467
	\$	1,277,185				344,489		37,888	53	168,539	31,377				18,067	77,970	42,931	4,560			99,579	2,102,638
2005	No.	3,848				176		74		254	30	1			223	430	88	20	2	1	265	5,412
	\$	1,312,762				338,660		40,007		171,403	34,100	1,049			16,894	76,566	36,250	4,091	200	407	97,775	2,130,164
2006	No.	3,909				173		76		273	26	3			218	405	73	14		2	263	5,435
	\$	1,293,880				339,616		40,067		173,304	31,292	4,365			16,558	70,650	28,726	2,983		649	96,055	2,098,145
2007	No.	3,849				172		73		285	22	3			284	437	48	19		2	278	5,472
	\$	1,266,622				326,968		38,232		177,423	24,295	4,212			21,640	78,748	16,739	4,042		495	93,677	2,053,093
2008	No.	3,732	2			158	2	70		294	25	3			256	466	36	22		2	312	5,380
	\$	1,250,346	1,651			305,250	497	36,287		174,254	20,872	4,366			19,597	92,120	13,770	4,725		302	97,439	2,021,476
2009	No.	3,573	3			151	29	63		326	32	2			239	447	25	27	1		261	5,179
	\$	1,248,939	3,313			302,270	7,186	32,640		218,798	31,320	1,584			18,401	91,537	9,094	5,823	100	79	91,954	2,063,038
2010	No.	3,655	5	1		140	55	61		275	43	1			181	415	16	24			207	5,079
	\$	1,323,673	6,021	2,512		280,531	13,665	31,498		200,424	36,209	1,252			14,195	83,950	5,583	7,539		8	85,669	2,092,729
2011	No.	3,648	8			129	71	59		290	65	2	1		127	442	9	23			144	5,019
	\$	1,331,635	7,639			259,230	17,239	30,327		194,142	47,100	5,874	255		9,646	88,481	3,166	9,183			84,054	2,088,352
2012	No.	3,526	7	2		122	76	48		326	84	1	1	5	172	439	3	19			190	5,021
	\$	1,318,483	7,289	4,584		243,599	18,531	23,972		204,957	53,457	1,031	100	13,467	13,132	86,384	1,182	7,772			77,355	2,075,295
2013	No.	3,306	5	2	5	124	72	38		324	98	1	1	11	199	441	2	28			159	4,816
	\$	1,182,491	2,528	4,755	1,846	231,618	16,639	16,900		204,023	57,050	1,147	306	23,554	15,286	82,799	662	11,939			71,260	1,924,803



EXCLUDES projects awarded with the Stamp Out Breast Cancer Funds and Program Evaluation.
In 2011, NCI awarded 1 UA5, it is not displayed but is included in the 2011 totals.

Activity Code Descriptions

R01	Research Project (Traditional) - discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specified interest and competencies.
DP1	NIH Director's Pioneer Award (NDPA) - Support for individuals who have the potential to make extraordinary contributions to medical research. Not renewable
DP2	NIH Director's New Innovator Awards - support exceptionally creative new investigators who propose highly innovative projects that have the potential for unusually high impact. This award complements ongoing efforts by NIH and institutes to fund new investigators through R01 grants and other mechanisms.
P01	Research Program Projects - broadly based, multidisciplinary, often long-term, research program which has a specific major objective or a basic theme. A program project is directed toward a range of problems having a central research focus in contrast to the usually narrower thrust of the traditional research project.
R00	Research Transition Award - To support the second phase of a Career/Research Transit award program that provides 1-3 years of independent research support (R00) contingent on securing an independent research position.
R35	Outstanding Investigator Grants - long-term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential in a categorical program area.
R37	Methods to Extend Research in Time (MERIT) Award - long-term support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Program staff and/or members of the cognizant National Advisory Council/Board may identify award candidates during the course of review of competing research grant applications prepared and submitted in accordance with regular PHS requirements.
R29	First Independent Research Support and Transition (FIRST) Award - sufficient initial period of support for newly independent biomedical investigators to develop their capabilities and demonstrate the merit of their ideas.
RFA	Request for Applications - A formal statement inviting grant or cooperative agreement applications in a well-defined scientific area to accomplish specific program purposes.
U01	Research Project Cooperative Agreement - discrete, specified, circumscribed project to be performed by investigator(s) in an area representing his/her specific interest and competencies.
U19	Research Program Cooperative Agreements - support programs with multiple projects directed towards specific major objective, basic theme, or program goal, requiring a broad-based, multidisciplinary, or long-term approach.
UH2	Exploratory/Developmental Cooperative Agreement Phase I - Supports the development of new research activities in categorical program areas. Support generally limited in time and amount.
UA5	Academic Research Enhancement Award (AREA) Cooperative Agreements - support cooperative agreements for the AREA program, which supports small-scale faculty research projects at baccalaureate degree-granting institutions.
UM1	Multi-Component Research Project Cooperative Agreements - support large-scale cooperative agreements involving complex clinical trials with multiple components.
R03	Small Grants - research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies. Generally for preliminary short-term projects. Non-renewable.
R15	Academic Research Enhancement Award (AREA) - to domestic health professional schools and other institutions offering baccalaureate or advanced degrees in health sciences, except those that have received NIH research grants and/or cooperative agreements. Supports feasibility studies and other small-scale research projects.
R21	Exploratory/Developmental Grants - Phase I development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R33	Exploratory/Developmental Grants - Phase II development of new research activities in categorical program areas. Support generally is limited in amount and time.
R55	Shannon Awards - limited support to scientists whose applications fall short of the cutoff for funding yet are at the "margin of excellence," i.e., the quality of the application is statistically indistinguishable from those that are funded.
R56	High-Priority, Short-Term Project Award - limited, non-renewable interim support to enable an applicant to gather additional data for revision of a new or competing renewal application.
R41	Small Business Technology Transfer (STTR) Grants - Phase I - limited support to projects conducted jointly by a small business and a research institution. Not less than 40% of the work is performed by the small business.
R42	Small Business Technology Transfer (STTR) Grants - Phase II - limited support to projects conducted jointly by a small business and a research institution. Not less than 40% of the work is performed by the small business.
R43	Small Business Innovation Research (SBIR) Grants - Phase I - projects limited in time and amount, to establish the technical merit and feasibility of R&D ideas which may ultimately lead to commercial products or services.
R44	Small Business Innovation Research (SBIR) Grants - Phase II - in-depth development of R&D ideas whose feasibility has been established in Phase I and which are likely to result in commercial products or services.
U43	Small Business Innovation Research (SBIR) Cooperative Agreement - Phase I - used when substantial programmatic involvement is anticipated between the institute and the recipient. Supports projects limited in time and amount to establish the merit and feasibility of R&D ideas that may lead to commercial products or services.
U44	Small Business Innovation Research (SBIR) Cooperative Agreement - Phase II - used when substantial programmatic involvement is anticipated between the institute and the recipient. Supports in-depth development of R&D ideas with established feasibility in Phase I and are likely to result in commercial products or services.

Research Project Grant Funding Mechanisms


Fiscal Years 2012 and 2013

Grant Funding Paylines

<u>RPG Mechanisms:</u>	<u>2012</u>	<u>2013</u>	
R01 Traditional Grants	7th	9th	Percentile
P01 Program Projects*	N/A	N/A	SPL Selected
R03 Small Grants	25	25	Impact Score
R21 Exploratory Phase I	7th	9th	Percentile
R33 Exploratory Phase II	N/A	N/A	SPL Selected
R41/R42 STTR	23	28	Impact Score
R43/R44 SBIR	24	28	Impact Score

*SPL = Scientific Program Leaders (NCI)

FY 2013 Percent Share of Total RPG Funds



Cancer Centers by State (P30 Core Grants), Fiscal Year 2013

State	Grantee Institution	Code	Count	Amount (Dollars in Thousands)
Alabama	University of Alabama at Birmingham	Comprehensive Core	1	\$5,120
Arizona	University of Arizona	Comprehensive Core	1	3,677
California	Burnham Institute for Medical Research	Basic Core	1	3,710
	City of Hope/Beckman Research Institute	Comprehensive Core	1	2,042
	Salk Institute for Biological Studies	Basic Core	1	2,745
	Stanford University	Clinical Core	1	2,891
	University of California San Diego	Comprehensive Core	1	3,548
	University of California Davis	Comprehensive Core	1	3,034
	University of California Irvine	Comprehensive Core	1	1,168
	University of California Los Angeles	Comprehensive Core	1	4,528
	University of California San Francisco	Comprehensive Core	1	7,004
	University of Southern California	Comprehensive Core	1	5,870
Colorado	University of Colorado Denver	Comprehensive Core	1	3,430
Connecticut	Yale University	Comprehensive Core	1	2,531
Dist of Col	Georgetown University	Comprehensive Core	1	1,450
Florida	H. Lee Moffitt Cancer Center & Research Institute	Comprehensive Core	1	2,840
Georgia	Emory University	Clinical Core	1	1,396
Hawaii	University of Hawaii at Manoa	Comprehensive Core	1	1,064
Illinois	Northwestern University at Chicago	Comprehensive Core	1	4,636
	University of Chicago	Comprehensive Core	1	4,093
Indiana	Indiana Univ-Purdue Univ at Indianapolis	Clinical Core	1	1,257
	Purdue University West Lafayette	Basic Core	1	1,118
Iowa	University of Iowa	Comprehensive Core	1	2,310
Kansas	University of Kansas Medical Center	Clinical Core	1	1,307
Kentucky	University of Kentucky	Clinical Core	1	1,403
Maine	Jackson Laboratory	Basic Core	1	2,016
Maryland	Johns Hopkins University	Comprehensive Core	1	6,541
	University of Maryland Baltimore	Clinical Core	1	1,463
Massachusetts	Dana-Farber Cancer Institute	Comprehensive Core	1	10,436
	Massachusetts Institute of Technology	Basic Core	1	3,604
Michigan	University of Michigan at Ann Arbor	Comprehensive Core	1	5,801
	Wayne State University	Comprehensive Core	1	2,376
Minnesota	Mayo Clinic Rochester	Comprehensive Core	1	5,345
	University of Minnesota Twin Cities	Comprehensive Core	1	3,207
Missouri	Washington University	Comprehensive Core	1	4,196
Nebraska	University of Nebraska Medical Center	Clinical Core	1	1,397
New Hampshire	Dartmouth College	Comprehensive Core	1	2,923
New Jersey	Rutgers Cancer Institute of New Jersey	Comprehensive Core	1	2,758
New Mexico	University of New Mexico	Clinical Core	1	1,808
New York	Albert Einstein College of Medicine Yeshiva University	Clinical Core	1	3,590
	Cold Spring Harbor Laboratory	Basic Core	1	4,077
	Columbia University Health Sciences	Comprehensive Core	1	3,546
	New York University School of Medicine	Clinical Core	1	2,278
	Roswell Park Cancer Institute Corp	Comprehensive Core	1	3,763
	Memorial Sloan-Kettering Institute for Cancer Res	Comprehensive Core	1	12,567
North Carolina	Duke University	Comprehensive Core	1	5,352
	University of North Carolina Chapel Hill	Comprehensive Core	1	6,721
	Wake Forest University Health Sciences	Comprehensive Core	1	1,063
Ohio	Case Western Reserve University	Comprehensive Core	1	4,740
	Ohio State University	Comprehensive Core	1	4,284
Oregon	Oregon Health and Science University	Clinical Core	1	1,062
Pennsylvania	Fox Chase Cancer Center	Comprehensive Core	1	4,098
	Thomas Jefferson University	Clinical Core	1	2,648
	University of Pennsylvania	Comprehensive Core	1	7,217
	University of Pittsburgh at Pittsburgh	Comprehensive Core	1	5,055
	Wistar Institute	Basic Core	1	2,308
South Carolina	Medical University of South Carolina	Clinical Core	1	1,310
Tennessee	St. Jude Children's Research Hospital	Comprehensive Core	1	5,527
	Vanderbilt University	Comprehensive Core	1	5,601
Texas	Baylor College of Medicine	Clinical Core	1	3,093
	University of Texas M.D. Anderson Cancer Center	Comprehensive Core	1	9,726
	University of Texas San Antonio Health Science Center	Clinical Core	1	651
	University of Texas Southwestern Medical Center	Clinical Core	1	1,332
Utah	University of Utah	Clinical Core	1	1,433
Virginia	University of Virginia Charlottesville	Clinical Core	1	2,332
	Virginia Commonwealth University	Clinical Core	1	1,331
Washington	Fred Hutchinson Cancer Research Center	Comprehensive Core	1	10,073
Wisconsin	University of Wisconsin Madison	Comprehensive Core	1	4,134
Total P30s			68	248,953
Planning Grants (P20s)			14	2,262
Other P20, P30 & U41			0	11,017
Total Cancer Centers			68	262,232

Specialized Programs of Research Excellence (SPOREs) Fiscal Year 2013

(Dollars in Thousands)


In 1992, the NCI established the Specialized Programs of Research Excellence (SPORE). The Translational Research Program (TRP) is the home of the SPOREs, a cornerstone of NCI's efforts to promote collaborative, interdisciplinary translational cancer research. SPORE grants involve both basic and clinical/applied scientists, and support projects that will result in new and diverse approaches to the prevention, early detection, diagnosis and treatment of human cancers.

Each SPORE is focused on a specific organ site, such as breast or lung cancer, or on a group of highly related cancers, such as gastrointestinal cancers. SPOREs are designed to enable the rapid and efficient movement of basic scientific findings into clinical settings, as well as to determine the biological basis for observations made in individuals with cancer or in populations at risk for cancer.

For more information, visit the Translational Research Program at <http://trp.cancer.gov>.

Mechanism	Site	No.	Amount
P50 SPOREs	Brain	4	\$8,428
	Breast	4	10,175
	Cervical	1	2,262
	Genitourinary	2	4,050
	Gastrointestinal	5	10,279
	Head and Neck	3	4,861
	Leukemia	3	6,452
	Lung	5	6,094
	Lymphoma	3	6,468
	Myeloma	2	4,301
	Ovarian	5	10,696
	Pancreatic	2	3,384
	Prostate	8	14,465
	Skin	5	10,261
	Uterine	1	1,418
Subtotal		53	103,595
P20	Brain	1	700
	Total P20	1	700
Co-funded	Head & Neck with NIDCR		1
	Total Co-funded		1
Total Number of SPOREs, Total SPORE Funding		54	\$104,296

National Research Service Awards (NRSAs)
Predoc and Postdoctoral Trainees, Fiscal Years 2004-2013
(Full Time Trainee Positions)



Research Career Awards "K" Program Fiscal Years 2012 and 2013

Number Awarded, Amount Funded, Percent of Total Awards Funded


The Research Career Award mechanism decreased by 0.8% in FY 2013

The number of Research Career Awards decreased by 35 between FY 2012 and FY 2013

NCI funded 50 awards for the NIH Pathway to Independence Program

		2012		2013	
		No.	Amount	No.	Amount
(Dollars in Thousands)					
K01	Temin Awards	51	\$1,110	10	\$1,284
K01	Minority Mentored Career Development Award		6,265	41	5,247
Subtotal, K01s		51	7,375	51	6,531
K05	Research Scientist Award	23	3,741	19	2,742
K07	Preventive Oncology	76	12,257	63	9,419
K08	Clinical Investigator	105	14,129	100	16,094
K12	Institutional Clinical Oncology Research	18	12,424	18	12,763
K18	Career Enhancement Award for Stem Cell Research	1	117	0	0
K22	Transition Career Development	25	4,827	21	3,562
K23	Patient-Oriented Career	36	5,937	35	5,823
K24	Patient-Oriented Career -- Mid Career	17	2,860	15	2,599
K25	Mentored Quantitative Research Career Development Award	17	2,868	15	2,061
K99	NIH Pathway to Independence Awards	53	7,080	50	5,930
Total Research Career Program		422	\$73,615	387	\$67,524

FY 2013 Percent of Total Research Career Award Funds



Grant and Contract Awards by State, Fiscal Year 2013

(Dollars in Thousands)

State	Grants		Contracts		Total	
	No	Amount	No	Amount	No	Amount
Alabama	64	\$28,506	4	\$1,407	68	\$29,913
Arizona	61	30,359	1	1,059	62	31,418
Arkansas	15	6,741			15	6,741
California	851	408,633	33	24,304	884	432,937
Colorado	99	29,440	1	250	100	29,689
Connecticut	82	29,408	1	2,023	83	31,431
Delaware	3	2,319			3	2,319
District of Columbia	63	24,514	10	5,839	73	30,353
Florida	175	64,105	5	1,847	180	65,953
Georgia	101	31,510	9	6,056	110	37,566
Hawaii	18	14,608	1	1,067	19	15,675
Idaho					0	0
Illinois	234	93,542	8	5,774	242	99,316
Indiana	61	19,212			61	19,212
Iowa	35	15,049	1	3,778	36	18,827
Kansas	29	13,018			29	13,018
Kentucky	54	17,137	3	1,458	57	18,596
Louisiana	38	9,859	1	1,428	39	11,288
Maine	5	4,113			5	4,113
Maryland	217	104,954	80	458,767	297	563,722
Massachusetts	612	327,220	9	3,344	621	330,563
Michigan	204	103,138	3	6,459	207	109,596
Minnesota	177	94,649	7	3,395	184	98,044
Mississippi	7	1,613			7	1,613
Missouri	112	46,140	7	5,594	119	51,734
Montana	3	866			3	866
Nebraska	36	17,501			36	17,501
Nevada	2	723			2	723
New Hampshire	43	19,451	2	229	45	19,679
New Jersey	71	26,866	3	4,912	74	31,778
New Mexico	24	11,213	1	2,418	25	13,630
New York	587	264,627	6	3,171	593	267,798
North Carolina	275	107,541	10	3,959	285	111,499
North Dakota					0	0
Ohio	210	93,408	5	5,189	215	98,597
Oklahoma	11	3,185	2	2,636	13	5,822
Oregon	40	20,968	1	200	41	21,168
Pennsylvania	466	226,668	5	858	471	227,525
Rhode Island	23	8,006	2	162	25	8,168
South Carolina	64	20,577	1	295	65	20,872
South Dakota	7	2,340			7	2,340
Tennessee	184	88,662	2	2,999	186	91,662
Texas	458	196,692	9	7,006	467	203,698
Utah	52	20,814	1	1,469	53	22,282
Vermont	8	5,860			8	5,860
Virginia	82	53,156	17	17,617	99	70,773
Washington	220	139,332	8	13,394	228	152,726
West Virginia	4	1,255			4	1,255
Wisconsin	95	41,054	1	1,702	96	42,756
Wyoming	1	142			1	142
Subtotal	6,283	2,890,691	260	602,066	6,543	3,492,757
Guam	1	939			1	939
Puerto Rico	7	4,337			7	4,337
Total	6,291	2,895,966	260	602,066	6,551	3,498,032

Excludes Stamp Out Breast Cancer funds, NRSA, Loan Repayment Program, Foreign Contracts and Grants, Program Evaluation, and other assessments and miscellaneous expenses.

Grant and Contract Awards by Country Fiscal Year 2013

(Dollars in Thousands)

<u>Country</u>	<u>Grant</u>		<u>Contract</u>		<u>Total</u>	
	<u>No</u>	<u>Amount</u>	<u>No</u>	<u>Amount</u>	<u>No</u>	<u>Amount</u>
Australia	3	\$673			3	\$673
Belgium	1	250			1	250
Canada	22	6,398	2	\$1,466	24	\$7,865
Costa Rica			1	2,280	1	2,280
France	6	2,769			6	2,769
India	1	184			1	184
Israel	5	1,119			5	1,119
Korea	1	161			1	161
Malawi	0	143			0	143
Netherlands	1	204			1	204
Sweden	1	50				50
Switzerland	0	250			0	250
United Kingdom	6	1,478	1	11	7	1,489
Total Foreign	47	13,679	4	3,758	50	17,436

Excludes Stamp Out Breast Cancer funds, NRSA, Loan Repayment Program, Foreign Contracts and Grants, Program Evaluation, and other assessments and miscellaneous expenses.

A "0" indicates an award funded by other NIH Institutes that NCI also co-funded.

Institutions Receiving More than \$15 Million in NCI Support Fiscal Year 2013

(Dollars in Thousands)

State	Institution	Grants	Contracts	Total NCI
Alabama	University of Alabama at Birmingham	\$25,437	\$832	\$26,268
Arizona	University of Arizona	18,671	1,059	19,731
California	Burnham Institute for Medical Research	19,757	0	19,757
	City of Hope's Beckman Research Institute	24,121	0	24,121
	Stanford University	51,858	0	51,858
	University of California System	166,501	456	166,958
	University of Southern California	35,350	3,144	38,494
Colorado	University of Colorado Health Sciences Center	20,481	0	20,481
Connecticut	Yale University	25,874	0	25,874
District of Columbia	Georgetown University	16,764	3,397	20,161
Florida	H. Lee Moffitt Cancer Center & Research Institute	29,324	368	29,691
Georgia	Emory University	20,912	2,031	22,943
Illinois	Northwestern University	28,032	492	28,524
	University of Chicago	24,402	694	25,095
	University of Illinois at Chicago	17,133	544	17,677
Iowa	University of Iowa	12,851	3,778	16,629
Maryland	The Johns Hopkins University	70,157	0	70,157
	SAIC-Frederick, Inc.	0	271,392	271,392
	Westat, Inc.	0	30,874	30,874
Massachusetts	Beth Israel Deaconess Medical Center	18,350	0	18,350
	Brigham and Women's Hospital	50,511	0	50,511
	Dana-Farber Cancer Institute	72,445	0	72,445
	Harvard University	23,774	0	23,774
	Massachusetts General Hospital	46,966	0	46,966
	Massachusetts Institute of Technology	22,633	0	22,633
Michigan	University of Michigan at Ann Arbor	69,033	0	69,033
	Wayne State University	13,770	3,711	17,481
Minnesota	Mayo Clinic in Rochester	57,394	2,042	59,436
	University of Minnesota	30,359	109	30,468
Missouri	Washington University	39,957	0	39,957
New Hampshire	Dartmouth College	18,686	0	18,686
New York	Columbia University Health Sciences	30,535	0	30,535
	Mount Sinai School of Medicine	22,080	0	22,080
	New York University	20,478	0	20,478
	Roswell Park Cancer Institute Corporation	29,789	0	29,789
	Sloan-Kettering Institute for Cancer Research	66,041	1,770	67,811
	Yeshiva University	20,045	0	20,045
	Duke University	34,171	0	34,171
North Carolina	University of North Carolina at Chapel Hill	48,532	0	48,532
	Case Western Reserve University	23,133	0	23,133
Ohio	Ohio State University	41,289	1,068	42,357
Oregon	Oregon Health and Science University	15,113	0	15,113
Pennsylvania	University of Pennsylvania	58,085	40	58,125
	University of Pittsburgh	49,791	511	50,303
	Wistar Institute	16,072	0	16,072
	Children's Hospital of Philadelphia	35,027	0	35,027
	Research Institute of Fox Chase Cancer Center	17,003	0	17,003
Tennessee	St. Jude Children's Research Hospital	21,325	0	21,325
	Vanderbilt University	58,900	0	58,900
Texas	Baylor College of Medicine	27,950	0	27,950
	University of Texas, MD Anderson Cancer Center	96,291	3,366	99,657
	University of Texas, SW Medical Center at Dallas	19,431	0	19,431
Utah	University of Utah	19,844	1,469	21,313
Virginia	American College of Radiology	23,503	0	23,503
Washington	Fred Hutchinson Cancer Research Center	85,946	9,815	95,761
	University of Washington	34,257	0	34,257
Wisconsin	University of Wisconsin	27,169	1,702	28,871
	Total	\$2,013,300	\$344,662	\$2,357,962

Includes Manpower Development Grants

Appropriations of the NCI, 1938-2014

(In Whole Dollars)

1938 - 2002	\$52,940,982,220	
2003.....	4,622,394,000	<i>prior to reductions in PL 108-7(-\$30,046,000 for the enacted rescission and -\$2,000 lapse). Includes \$263,442,000 of AIDS funding.</i>
2004.....	4,770,519,000	<i>prior to reductions in PL 108-199(-\$3,136,000 for Labor/HHS/ED rescission; \$28,128,000 for across the board reduction; -\$15,357,000 NIH 1% transfer assessment, and \$5,000 lapse). Includes \$266,975,000 of AIDS funding.</i>
2005.....	4,865,525,000	<i>prior to reductions in PL 108-447(\$38,914,000 .8% across the board reduction; -\$1,353,000 for Labor/HHS/ED rescission; -\$30,505,000 NIH 1% transfer assessment, and \$9,000 lapse). Includes \$265,907,000 of AIDS funding.</i>
2006.....	4,841,774,000	<i>prior to reductions in PL 109-149 (-\$48,418,000 for Labor/HHS/ED rescission; -\$3,293,000 HHS transfer for CMS activities; -\$42,834,000 NIH 1% transfer for roadmap activities, and \$4,000 lapse). Includes \$253,866,000 of AIDS funding.</i>
2007.....	4,797,639,000	<i>prior to reductions in PL 110-5 (-\$5,015,000 NIH transfer for GEI activities, and \$9,000 lapse). Includes \$253,866,000 of AIDS funding.</i>
2008.....	4,827,556,000	<i>Includes supplemental appropriation of \$25,559,000. Includes \$258,499,000 of AIDS funding.</i>
2009.....	4,968,973,000	<i>prior to reductions in PL 111-8 (-\$2,042,631 NIH transfer for activities, and \$4,000 lapse). Includes \$265,882,000 of AIDS funding.</i>
2010.....	5,103,388,000	<i>prior to -\$760,000 HHS Secretary's transfer ,-\$4,459,000 in NIH transfer for activities, and \$22,000 lapse. Includes \$272,130,000 of AIDS funding.</i>
2011.....	5,058,577,000	<i>prior to \$472,000 lapse. Includes \$269,953,000 of AIDS funding.</i>
2012.....	5,072,183,000	<i>prior to -\$1,445,000 HHS Secretary's transfer ,-\$3,342,000 HHS Secretary's transfer for Alzheimer's research, and \$54,000 lapse. Includes \$271,692,000 of AIDS funding.</i>
2013.....	5,072,183,000	<i>prior to -\$254,589,000 under sequestration (Budget Control Act, 2011, PL 112-25), -28,044,000 HHS Secretary's transfer and \$9,714,000 restored from the National Children's Study and National Eye Institute HIV/AIDS funding, and \$106,000 lapse. Includes 261,550,471 of AIDS funding.</i>
2014.....	4,923,238,000	<i>prior to -\$12,359,000 HHS Secretary's transfer. (As of publication date. Other 2014 transfer amounts pending.)</i>
1938-2014	\$111,864,931,220	

Professional Judgment (Bypass) Budget Requests Fiscal Years 1974-2015

(in Whole Dollars)

Fiscal Year	Request	Fiscal Year	Request
1974.....	\$640,031,000	2000.....	3,873,000,000
1975.....	750,000,000	2001.....	4,135,000,000
1976.....	898,500,000	2002.....	5,030,000,000
1977.....	948,000,000	2003.....	5,690,000,000
1978.....	955,000,000	2004.....	5,986,000,000
1979.....	1,036,000,000	2005.....	6,211,000,000
1980.....	1,055,000,000	2006.....	6,170,000,000
1981.....	1,170,000,000	2007.....	5,949,714,000
1982.....	1,192,000,000	2008.....	5,865,788,000
1983.....	1,197,000,000	2009.....	6,028,386,000
1984.....	1,074,000,000	2010.....	7,193,393,000
1985.....	1,189,000,000	2011.....	6,199,666,000
1986.....	1,460,000,000	2012.....	5,869,857,000
1987.....	1,570,000,000	2013.....	5,833,010,000
1988.....	1,700,000,000	2014.....	To be determined
1989.....	2,080,000,000	2015.....	To be determined
1990.....	2,195,000,000		
1991.....	2,410,000,000		
1992.....	2,612,000,000		
1993.....	2,775,000,000		
1994.....	3,200,000,000		
1995.....	3,600,000,000		
1996.....	3,640,000,000		
1997.....	2,977,000,000		
1998.....	2,702,500,000		
1999.....	3,191,000,000		


The National Cancer Act of 1971 (P.L. 92-218) gives NCI special authority to submit an annual budget estimate directly to the President. Each year, NCI develops the Professional Judgment Budget, commonly known as the Bypass Budget, which reflects NCI cancer research priorities and identifies areas of potential investment in cancer research. NCI submitted its first Professional Judgment Budget, often referred to as the Bypass Budget, for the FY 1974 request.

The NCI Bypass Budget authority in section 407 of the National Cancer Act provides:

The Director of the Institute in carrying out the National Cancer Program [shall] prepare and submit, directly to the President for review and transmittal to Congress, an annual budget estimate (including an estimate of the number and type of personnel needs for the Institute) for the National Cancer Program, after reasonable opportunity for comment (but without change) by the Secretary [of the Department of Health and Human Services], the Director of NIH, and the Institute's advisory council.

Bypass Requests and NCI Appropriations

Fiscal Years 1974-2014



Funding Trends

Fiscal Years 2009-2013

Funding amounts and percentages reflect actual obligations for each fiscal year.

The NCI Budget has decreased by \$178 million -- or 3.6% -- since 2009.

The mechanism shares of the total budget have remained relatively stable from FY 2009 to FY 2013.

	Funding				
	(Dollars in Millions)				
	2009	2010	2011	2012	2013
Total NCI	\$4,967.0	\$5,098.1	\$5,058.1	\$5,067.3	\$4,789.0
Research Project Grants	2,134.0	2,168.1	2,163.7	2,150.6	2,000.2
Cancer Centers	285.6	295.9	278.3	279.9	262.2
SPOREs	131.4	133.8	121.9	113.5	104.3
Other P50s/P20s	28	38.8	35.2	33.4	21.5
Other Specialized Centers	116.4	142.7	162.7	186.0	146.0
Clinical Cooperative Groups	234.5	254.5	243.9	229.8	235.4
R&D Contracts	610.1	613.8	587.0	589.7	616.0
Intramural Research	781.4	805.3	833.7	857.8	811.6
Other Mechanisms	645.5	645.4	631.8	626.5	591.8

	Percent Growth by Mechanism				
	2009 to 2010	2010 to 2011	2011 to 2012	2012 to 2013	2009 to 2013
Total NCI	2.6%	-0.8%	0.2%	-5.5%	-3.6%
Research Project Grants	1.6%	-0.2%	-0.6%	-7.0%	-6.3%
Cancer Centers	3.6%	-5.9%	0.6%	-6.3%	-8.2%
SPOREs	1.8%	-8.9%	-6.9%	-8.1%	-20.6%
Other P50s/P20s	38.0%	-9.3%	-4.9%	-35.8%	-23.6%
Specialized Centers	22.6%	14.0%	14.4%	-21.5%	25.4%
Clinical Cooperative Groups	8.5%	-4.2%	-5.8%	2.4%	0.4%
R&D Contracts	0.6%	-4.4%	0.5%	4.5%	1.0%
Intramural Research	3.1%	3.5%	2.9%	-5.4%	3.9%
Other Mechanisms	0.0%	-2.1%	-0.8%	-5.5%	-8.3%

	Percent Share of Total NCI Dollars				
	2009	2010	2011	2012	2013
Research Project Grants	43.0%	42.5%	42.8%	42.4%	41.8%
Cancer Centers	5.8%	5.8%	5.5%	5.5%	5.5%
SPOREs	2.6%	2.6%	2.4%	2.2%	2.2%
Specialized Centers	2.3%	2.8%	3.2%	3.7%	3.0%
Other P50s/P20s	0.6%	0.8%	0.7%	0.7%	0.4%
Clinical Cooperative Groups	4.7%	5.0%	4.8%	4.5%	4.9%
R&D Contracts	12.3%	12.0%	11.6%	11.6%	12.9%
Intramural Research	15.7%	15.8%	16.5%	16.9%	16.9%
Other Mechanisms	13.0%	12.7%	12.5%	12.4%	12.4%


Extramural vs. In-house Funding Fiscal Years 2009-2013

(Dollars in Millions)

Extramural						
Mechanism	2009	2010	2011	2012	2013	09-13% chg.
Research Project Grants	\$2,137.0	\$2,168.1	\$2,163.7	\$2,150.6	\$2,000.2	-6.4%
Cancer Centers	285.6	295.9	278.3	279.9	262.2	-8.2%
SPOREs	131.4	133.8	121.9	113.5	104.3	-20.6%
Other P50s/P20s	28.1	38.8	35.2	33.4	22.2	-21.0%
Other Specialized Centers	116.4	142.7	162.7	186.0	145.3	24.8%
Other Research Grants	417.3	442.5	425.5	407.5	387.5	-7.1%
NRSA	70.1	67.6	67.7	66.0	65.8	-6.2%
R&D Contracts	610.1	613.8	587.0	589.7	616.0	1.0%
Construction	0.0	0.0	0.0	0.0	0.0	0.0%
Buildings & Facilities	7.9	7.9	7.9	7.9	7.9	0.1%
Total Extramural Funds	3,803.9	3,911.0	3,849.9	3,834.5	3,611.5	-5.1%

In-house						
Mechanism	2009	2010	2011	2012	2013	09-13% chg.
Intramural Research	\$781.4	\$805.3	\$833.7	\$857.8	\$811.6	3.9%
RMS	384.6	381.8	374.5	374.9	366.1	-4.8%
Total In-house Funds	1,166.0	1,187.1	1,208.2	1,232.8	1,177.6	1.0%
Total NCI	4,969.9	5,098.1	5,058.1	5,067.3	4,789.1	-3.6%

Extramural vs. In-house Funding FY 2009 - 2013





Comparison of Dollars, Positions, and Space Fiscal Years 2004-2013

Funds are obligations against the annual appropriation in millions of dollars.

FTEs are the number of work years for appointed employees of the NCI. A work year equals 2,080 hours.

Space is in thousands of square feet, excluding NCI-Frederick.

The increase in space (Sq Ft) during FY 2013 is due to NCI's lease of its Shady Grove complex, a new consolidated facility in Rockville, MD. This facility has the advantage of providing additional space for NCI scientific programs, and includes conference and meeting rooms, a cafeteria and a data center that serves multiple NCI facilities. During FY 2013, NCI was working to decommission their vacated leased facilities, and must continue to lease a portion of them as they complete the decommissioning process.



NCI Personnel
Fiscal Years 2003-2013


Fiscal Year	Full Time Permanent Appointment	Other than Full Time Permanent	Training Fellows	Total Personnel Resources
2003	2,193	1,073	1,191	4,457
2004	2,083	990	1,232	4,305
2005	1,959	882	1,077	3,918
2006	2,579	289	1,113	3,981
2007	2,421	498	1,111	4,030
2008	2,075	920	1,016	4,011
2009	2,118	959	1,058	4,135
2010	2,148	1,011	1,073	4,232
2011	2,180	1,029	1,108	4,317
2012	2,139	997	906	4,042
2013	2173	948	847	3,968

AIDS Funding History

Fiscal Years 1996 - 2013

(Dollars in Thousands)

Fiscal Year	NCI	NIH	% NCI of NIH
1996	\$225,360	\$1,411,860	16%
1997	224,733	1,501,073	15%
1998	225,991	1,559,071	14%
1999	239,190	1,797,422	13%
2000	244,145	2,005,100	12%
2001	237,789	2,244,160	11%
2002	254,396	2,500,866	10%
2003	263,442	2,718,171	10%
2004	266,975	2,840,384	9%
2005	265,907	2,909,381	9%
2006	253,666	2,902,183	9%
2007	253,666	2,904,536	9%
2008	258,499	2,928,300	9%
2009	265,882	3,019,279	9%
2010	272,130	3,085,597	9%
2011	269,953	3,059,243	9%
2012	271,692	3,076,056	9%
2013	261,550	2,897,865	9%





NIH Publication No. 14-7874
Printed June 2014

